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During breast tumor development, extra energy is required to support the 
uncontrolled growth. This energy is supplied by increased glucose or fructose uptake, 
through the agency of facilitative glucose transporters, and their catabolism. By 
reducing the uptake of these monosaccharides, tumor proliferation would be inhibited 
as a result of nutrient deprivation. To test this hypothesis, antisense oligonucleotides 
(AS) against glucose transporter 5 (Glut 5), which is also called fructose transporter, 
were synthesized to block its expression in breast tumor cells. Antisense treatment 
represents the regulation of gene expression by short oligonucleotides or 
oligonucleotide mimics, which relies on various mechanisms including the formation 
of Waston and Crick hydrogen bonds between the antisense oligomer and the 
complementary mRNA strand, thereby providing target specificity of the agent. 
The sequence of AS(s) were complementary to Glut 5 mRNA, with 15 base 
pairs in length. The antisense oligonucleotides were then phosphorothioated at each 
base to increase the stability. In the present study, antisense oligonucleotides were 
transfected into two human breast tumor cell lines, an estrogen receptor positive cell 
line MCF-7 and an estrogen receptor negative cell line MDA-MB-231, to investigate 
the effect of these oligonucleotides on the breast tumor growth, which includes 
cytotoxic effect, regulation of Glut 5 gene expression, uptake efficiency of 
vi 
monosaccharides, intracellular ATP content, cell cycle pattern and apoptotic study 
after AS treatment and in vivo study. 
For in vitro study, it was found that after 72-hour incubation of various 
concentration of AS, the percentages of survival of MCF-7 cells and MDA-MB-231 
cells were decreased in a dose dependent manner. Significant inhibition (>30% in 
both cell lines) of fructose uptake was observed and was accompanied by the 
reduction of Glut 5 mRNA and protein level (>40% in both cell lines). The 
intracellular ATP content was decreased in both MCF-7 cells and MDA-MB-231 cells. 
In addition, apoptosis was found in both cell lines, with the incidence of 
phosphatidylserine extemalization and the occurrence of apoptotic peaks after 
72-hour incubation at I C 5 0 concentration, namely 220nM, 190nM, 300nM and 220nM 
for AS 1，AS 2，AS 3 and AS 4 respectively in MCF-7 cells，and 410nM, 400nM， 
400nM and 470nM for AS 1, AS 2，AS 3 and AS 4 respectively in MDA-MB-231 
cells. 
For in vivo study, AS was injected to the MCF-7-cells-bearing female nude 
mice at 20mg/kg/day, just adjacent to the tumor. Treatment of AS decreased the tumor 
» 
growth rate, when compared with PBS and sense control. The expression of Glut 5 
mRNA and protein were also suppressed. Moreover, treatment of AS did not cause 
any side effects on the liver and heart of the host. In conclusion, AS were effective in 
vii 
treating breast cancer in vitro and in vivo. The ultimate goal is to develop an effective 
approach to human breast cancer treatment by using novel chemically modified 






果糖主要是透過其細胞膜葡萄糖運输體(Glucose transporters, G lu t s )� 
我們假設當這些單糖的攝取量減低時’癌細胞的生長速度會降低或令 
細 胞 调 亡 。 因 此 ’ 我 們 設 計 了 反 義 寡 核 糖 核 酸 （ A n t i s e n s e 




這些長度為十五個驗a基 (Base)的反義寡核糖核酸是與Glut 5的 
信使核糖核酸互補的。為了提升寡核糖核酸的穩定性，我們選用了一 
種經琉化碟酸醋改良的低聚核甘酸。在這項研究中’反義寡核糖核酸 








隨著劑量的提高，存活率亦相對減少。Glut 5反義寡核糖核酸A S 1-4 
對 MCF-7 癌細胞的 ICso 分別為 2 2 0 i i M � 1 9 0 | L I M� 3 0 0 |LIM 和 220 
|LIM。而對 MDA-MB-231 癌細胞則為 4 1 0 | l i M �4 0 0 | l i M � 4 0 0 [iM 和 









降了 °另外，G l u t 5的信使核糖核酸和蛋白量亦減少了。與此同時， 
反義寡核糖核酸並沒有對棵鼠的心職和肝職構成傷害。 
總括來說，反義寡核糖核酸有效地治療體内及體外的乳癌’這項 
研究的最終目的是能夠利用化學改良Glu t 5反義寡核糖核酸去開發 
一種治療乳癌的有效方法。 
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1.1 Breast Cancer 
1.1.1 Incidence Rate of Breast Cancer 
Breast cancer is the most common cancer among females in Hong Kong 
since the early 1990,s. It is accounting for almost 20% of all new cases of cancers in 
females diagnosed in Hong Kong. The incidence rate is increasing during the past 20 
years, from 33.1 per 100 000 female population in 1983 to 56.6 per 100 000 in 2000, 
according to the annual report of the Department of Health (Fig. 1.1). The risk of 
breast cancer starts to rise from the age of 35, with the peak incidence at age 50 and 
above. Breast cancer is the third commonest cause of female cancer death in Hong 
Kong. In 2002, a total of 425 women died from this cancer, accounting for about 





侧 • n _ _ _ i ® I 
i n F l " ! ! 丨 
nnnnlHf 11 III 
I:""丨”④；• 
i III Itl 111 y _ t i lil III U11 Ml Q 
19S4 i m 1988 1990 1992 1994 1996 1998 2000 
Year 
[•Newcases ""Incidence rate | 
Figure 1.1 
Chart showing the number of new cases per 100 000 female population and 
incidence rate of breast cancer in Hong Kong (Adapted from Census and Statistics 






B - / 
\ / \ z 广 〜 " “ � \ / 
V - ' ‘ 
召 | | 6 -
I 2 I 
§ to 4 _ 
I 
S 2 -
0 �… ,“"“Iii‘�i,.i……I—I~III~aI—I_I—IIIt I I I I 1 » 
1982 1984 i m m t 1990 1992 1994 1996 1998 2000 
Year 
Figure 1.2 
Chart showing the age-standardized death rate in Hong Kong in recent 20 years 




1.1.2 Risk Factors Lead to Breast Cancer 
The risk of having breast cancer is increasing with the age, especially after 
the menopause. Breast cancer is more common among nulliparous women or women 
having their first child late. Women who have early menarche and late menopause 
are also at higher risk. Other risk factors include personal or family history of breast 
cancer and previous history of certain benign breast diseases. The disease may be 
related to a high fat diet as well. 
1.1.3 Conventional Treatments 
In recent years, there has been an advance in treatments against breast 
cancer. Conventional treatments include surgical removal, radiotherapy, 
immunotherapy, chemotherapy and hormonal therapy. 
Breast cancer is stimulated by the body's own estrogens. Stopping the 
body's estrogen reaching the breast cells can inhibit growth of tumor or cause 
apoptosis of the cancer cells. Tamoxifen is the most widely used anticancer drug in 
‘ t r e a t i n g breast cancer. Tamoxifen stops estrogen stimulating a cancer cell in two 
» 
main ways. First, it binds to the estrogen receptor (ER) and inhibits the binding of 
body's own estrogen. Thus, it acts as an estrogen antagonist. It suppresses growth 




As its action depends on ER, if a tumor is ER-positive, it is much more likely 
to respond to tamoxifen. Tamoxifen fails to treat advanced stage breast cancer, 
which is lack of ER, i.e. ER-negative breast cancer. Besides, tamoxifen has many 
potential side effects, e.g. occurrence of hot flashes, increase risk of endometrial 
cancer and thromboembolic disease, etc. Also, many tumors eventually become 
resistant to treatment with tamoxifen (Sainsbury, 2004). 
Based on the high incidence and death rate and the failure of treatment 
today, novel breast cancer treatment has to be developed. 
6 
Introduction 
1.2 Relationship between Breast Cancer and Glucose 
Transporters 
1.2.1 Importance of Glucose and Fructose 
Glucose, fructose and other hexoses serve as basic fuel molecules for cancer 
cells. They were metabolized to provide energy to support the high metabolic rate of 
cancer cells. The hexoses are unable to diffuse across the cell membranes, and 
require the actions of transporter proteins for the entry into the cells. Two distinct 
groups of hexose transporter have been identified and classified basing on their 
dependence on energy. The first group is sodium-linked glucose co-transporters 
(SGLTs), which use the energy provided by an electrochemical gradient of sodium, 
and transport hexoses against a concentration gradient. The second group is 
facilitative glucose transporter (Gluts), which transport hexoses down a 
concentration gradient. 
1.2.2 Facilitative Glucose Transporters (Gluts) and The 
Relationship with Breast Cancer 
t 
Facilitative glucose transporters (Gluts) were found to have 13 isoforms, 
Glut 1 to Glut 13 (Joost and Thorens, 2001). The expression pattern of the Gluts was 




Tissue distribution of facilitative glucose transporters (Gluts) (Joost and Thorens, 
2001). 
Name Tissue distribution 
Glut 1 Present in many tissues; abundant in human erythrocytes, 
endothelial and many cell lines 
Glut 2 Hepatocytes, pancreatic cell, intestine and kidney 
Glut 3 Brain 
Glut 4 Skeletal muscle, heart and adipose tissue 
Glut 5 Intestine, spermatozoa and kidney 
Glut 6 Spleen, leukocytes and brain 
Glut 7 Microsomal glucose transporter in liver 
Glut 8 Testis, brain and blastocyst 
Glut 9 Kidney and liver 
Glut 10 Liver and pancreas 
Glut 11 Heart and skeletal muscle 
Glut 12 Heart and prostate 




The Glut proteins contain approximately 500 amino acids, with Glut 1-5 
exhibiting 39-65% sequence homology (Mueckler 1994). All Gluts share a common 
structural motif of 12 transmembrane helices with amino and carboxyl termini 
located in the cytosol. There is a large loop between transmembrane segments 6 and 
7, which divides Glut into 2 parts, the C-terminal domain and N-terminal domain 
(Gould and Holman, 1993). Also, N-linked glycosylation site is found between 
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The proposed two-dimensional structure of Glut family proteins, which consists of 
12 membrane-spanning regions with cytoplasmic C-terminal and N-terminal. Also, 
they all appear to be glycosylated on one of the extracellular loops (Adapted from 




Gluts were found to be over-expressed in many cancers. For example, 
over-expression of Glut 5 was found in breast cancer cells (Fig. 1.4，Zamora-Leon et 
al, 1996). Over-expression of Glut was observed in cancer cells because of their 
different mechanism in the catabolism of hexose. Most cancer cells are anaerobic 
cells in which catabolism of hexose stopped after glycolysis, and did not further 
enter Krebs cycle for mass production of energy. Therefore, little energy can be 
produced by a hexose molecule. In fact, tumor cells require a large amount of energy 
to support their high growth rate. So, the cells express more glucose transporters as 
adaptive mechanism in order to survive. 
As mentioned in the previous part, expression of Glut 5 was found in vivo 
in human breast cancer but is absent in normal breast tissue (Zamora-Leon et aL, 
1996). This finding indicated that breast cancer cells may have specialized capacity 





Immunolocalization of Glut 5 in human breast tissue. Glut 5 is shown as a dark blue 
colour (Adapted from Zamora-Leon et al., 1996). 
(A) Immunohistochemistry of normal breast tissue. Mammary epithelial cells do not 
express Glut 5 as revealed by basal anti-Glut 5 reactivity; 
(B) Immunohistochemistry of human breast cancer tissue. High-expression of Glut 5 




1.3 Antisense Oligonucleotides 
1.3.1 Characteristics of Antisense Oligonucleotides 
Antisense represents the regulation of gene expression by short 
oligonucleotides or oligonucleotide mimics, which relies on the formation of Waston 
and Crick hydrogen bonds between the antisense oligomer and the complementary 
mRNA strand, thereby providing target specificity of the agent. 
Antisense oligonucleotide is a single-stranded, negatively charged DNA， 
which is designed complementary to the target nucleotide sequence. It forms a 
duplex with the target nucleotide sequence through the Waston and Crick base 
pairing. 
Antisense oligonucleotide was first introduced by Paterson et al (1977), 
by inhibiting single-stranded DNA translation in cell free system. It was later 
discovered that antisense oligonucleotide can be used for the treatment of Rous 
sarcoma infections (Zamecnik and Stephenson, 1978). From their early work, 
antisense oligonucleotides have progressed to become a powerful tool in molecular 
biology and as a therapeutic agent. By pairing with their cognate mRNA, antisense 
I 
oligonucleotides can knockdown gene expression specifically through several 
mechanisms which will be discussed later. The antisense oligonucleotide can also be 
an effective drug. It has been widely accepted as a tool to study gene functions and 
13 
Introduction 
to validate drug targets because it is economical and a short experimental cycle is 
needed (Flaherty et al.’ 2001). Although the applications of small interfering RNAs 
(siRNAs) as a new gene knockdown technology have shown significant advantages 
in some studies, antisense oligonucleotides still remain as a competitive alternative 




1.3.2 Action Mechanism of Antisense Oligonucleotides 
Antisense oligonucleotides are designed to bind to RNA through Watson and 
Crick hybridization. In general, their size ranges from 12-25 nucleotides in length 
(Dean and Bennett, 2003). There are multiple mechanisms that can be exploited to 
inhibit the function of the RNA once the oligonucleotide binds to the target RNA 
(Crooke, 1999). They are inhibition of transcription and mRNA translation. 
Inhibition of transcription is by binding of antisense DNA to the DNA duplex by 
hydrogen bonding and result in formation of DNA triplex. As a consequence, 
unwinding of the DNA strands and the DNA-polymerase mediated transcription are 
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The formation of DNA triplex after binding of antisense oligonucleotide to the DNA 





Other action mechanisms of antisense include the inhibition of mRNA 
translation by RNase H degradation, and modulation of RNA processing and steric 
hindrance, by blocking pre-mRNA function or interacting with ribosomes (Fig. 1.6A 
&B). 
The best characterized antisense mechanism is RNase H mediated 
degradation. RNase H is a family of ubiquitously expressed enzymes that cleave the 
RNA strand of an RNA-DNA hybrid, with at least two forms found in mammalian 
cells (Lima et aL, 2001). The target mRNA sequence is inactivated as an irreversible 
event since the antisense DNA may degrade several mRNA molecules, through 
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(A) The formation of antisense DNA and mRNA duplex and induction of RNase H 
cleavage ofDNA/RNAhybrid. 
(B) The binding of antisense DNA to the target mRNA and prevention of the binding 
ofribosomes by steric hindrance. 
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1.3.3 Sequence Selection 
Antisense oligonucleotide sequence selection is the most important step in 
the application of antisense technology. The effectiveness of an antisense 
oligonucleotide depends on the accessibility of the mRNA site to which it is intended 
to bind. Hybridization of antisense oligonucleotide to different regions of mRNA 
leads to different action mechanisms. For example, antisense complementary to the 
5' cap region or the start codon of mRNA can act through steric hindrance and 
prevent the binding of ribosomes. For the antisense complementary to the coding 
region of mRNA would trigger RNase H activity. It is necessary to characterize the 
efficacy, specificity and other properties of antisense oligonucleotides. There are 
many methods to identify the accessible sites include RNase H mapping, gel shift, 
oligonucleotide array and random RT priming, as well as computational predictions. 
Among them, RNase H mapping and random RT priming use short oligonucleotide 
libraries to determine the accessibility of mRNA have shown promising results 





1.3.4 Chemical Modifications of Antisense Oligonucleotides 
Oligonucleotides exert their activity only by encountering a sufficient 
intracellular concentration; a sufficient intracellular half-life; serum, body fluids and 
intracellular nuclease stability; and an efficient cellular uptake and distribution 
(Alama et al., 1997). Naturally occurring DNA is sensitive to enzymatic degradation 
by exonuclease and endonucleases, both in vivo and in vitro (serum-containing 
medium). In order to prevent rapid degradation by the nucleases, chemical 
modifications of the natural phosphodiester backbone have been developed. 
The three structural elements of oligonucleotides, the base, the 
phosphodiester group and the sugar, could be modified. Modifications to the base 
such as a methyl group have been shown to increase the binding affinity for both 
DNA and RNA (Fig. 1.7) (Flanagan et al” 1999). Modifications to the sugar are 
useful for enhancing the potency of the oligonucleotide and their pharmacokinetics. 
The most common modifications are 2'-0-methyl (OMe) and 2'-0-methoxyethyl 
(MOE) (Fig. 1.7). These modifications result in a 3-10 fold increase in nuclease 
resistance and decreased toxicity (Geary et al., 2001). Modifications of the 
phosphate group include phosphorothioated oligonucleotides or "morpholino" 
modification, which contains a neutral phosphorodiamidate linkage (Fig. 1.7) 
(Summerton et al., 1999). Peptide nucleic acid (PNA), with the sugar-phosphate 
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backbone is completely replaced with a peptide-based backbone, is a unique 
modification (Fig. 1.7). This results in a polymer with a neutral backbone that has a 
high affinity for complimentary nucleic acids and is completely resistant to 
degradation by nuclease and peptidases (Larsen et al., 1999). Of all the chemical 
modifications developed, phosphorothioated oligonucleotide is the most extensively 
studied analogs of the phosphodiester oligonucleotides and was evaluated for their 
therapeutic potential in human clinical trials (Dean and Bennett, 2003). 
In phosphorothioated oligonucleotides, one of the non-bridging oxygen 
atoms of the phosphate group is replaced with a sulfur atom in order to prevent rapid 
degradation by nucleases (Fig. 1.8). Additionally, phosphorothioated oligonucleotides 
possess important properties such as binding affinity to target mRNA, cellular 
uptake, aqueous solubility and the ability to activate RNase H, which is required for 
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Chemical modifications used in antisense oligonucleotides. 
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Phosphorothioated oligonucleotide, one of the non-bridging oxygen atom of the 




1.3.5 Uptake and Delivery Means of Antisense Oligonucleotides 
Antisense oligonucleotides are polyanoinic, they cannot penetrate the 
phospholipids bilayer due to their charge and polarity. Delivery vector was 
developed to mediate the entry and the delivery of antisense oligonucleotides to the 
target. The vector can also protect the drug from degradation and rapid clearance 
from the body. The size of vectors must be small to allow intercalation between 
tissues and to allow intracellular transport. If the vector is too large, this can enhance 
the clearance of the drug from the body. They must be non-toxic and stable in 
bloodstream, retain the drug when in the circulation and must release it at its target 
before elimination. There are many available drug delivery systems either based on 
natural or synthetic systems and many show great potential in delivering a molecule 
or drug to the target of interest either in molecular biology research or in 
therapeutics. The usage of liposomes, protein or peptide constructs and polymers 
were developed to provide the above properties (Szorka Jr et aL, 2000). 
Liposomes are small microscopic spheres of concentric, closed 
phospholipids bilayer enclosing an internal aqueous compartment, like the plasma 
I 
membrane of cells or of certain organelles. When oligonucleotides are mixed with 
lipids, complexes form spontaneously due to electrostatic interactions and form a 
condensed and tight structure (Gershon et aL, 1993). The liposome would be 
24 
Introduction 
endocytosed and caused disruption of the endosomal membrane, resulting in fusion 
and expulsion of the contents into cytoplasm (Zelphati et al. 1996). 
Antisense oligonucleotides can be conjugated to proteins and peptides that 
have the ability to penetrate the cell membrane without the liposome complex. The 
oligonucleotides attach by electrostatic interactions to poly-L-Lysines, or other 
cationic sequence, linked to a carrier molecule that is a ligand for a surface receptor 
similar to the targeting ligands in liposomes. The peptide complex can be protected 
from nucleases. A nuclear localization sequence (NLS) can be added to the protein 




1.4 Obj ectives of Present Study 
In the present study, the effects of antisense oligonucleotides against glucose 
transporter 5 (Glut 5) on two human breast cancer cell lines were investigated. 
MCF-7 cells possess the characteristics of differentiated mammary 
epithelium including ability to process estrogen via cytoplasmic estrogen receptors 
(ER) and the capability of forming domes. Their growth depends on estrogen. This 
cell line mimics the early stage of breast cancer, which is estrogen dependent. The 
doubling time is 41 hours (Fig. 1.9A). 
It was found that Glut 5 is highly expressed in breast cancer cells. The 
expression pattern is different in different cell lines (Zamora-Leon et al., 1996). For 
MCF-7 cells, less Glut 5 were expressed when compared with that of MDA-MB-231 
cells (Fig. 1.10). 
The growth of MDA-MB-231 cells is estrogen independent because they 
are lack of ER. This cell line mimics the late stage of breast cancer and was found to 
be more invasive and malignant than MCF-7 cells (Carmeci et al., 1998). The 
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The growth curve of (A) MCF-7 cells, (B) MDA-MB-231 cells (Adapted from the 
thesis of Chan KK). 
1x10^ cells per well were seeded in a 6-well plate overnight. Then, the cell number 
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The expression pattern of Glut 5 in different breast cancer cell lines. Lane 1 is 
MCF-7 cells and lane 2 is MDA-MB-231 cells. More Glut 5 was expressed in 
MDA-MB-231 cells when compared with MCF-7 cells (Zamora-Leon et a!., 1996). 
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As mentioned before, glucose transporters play an important role in 
transporting hexoses into the tumor cells, we hypothesized that blocking the 
expression of glucose transporters in tumor cells by using antisense oligonucleotides 
can reduce the nutrient supply. As a result, the growth of tumor may be suppressed 
due to the lack of nutrients. 
Glut 5 was chosen as the target of antisense oligonucleotides because of a 
couple of reasons. Glut 5 is localized in breast tumor cells, but it is absent in normal 
breast epithelial cells (Fig. 1.4); also, Glut 5 was only found in a few human normal 
tissues, i.e. intestine and spermatocytes. There are other isoforms of Gluts in 
intestine for the uptake of nutrients, e.g. Glut 1, and spermatocytes are found in male 
only. Targeting Glut 5 in human breast tumor cells in female is highly specific and 
will not affect the normal function of the surrounding normal breast tissues and other 
organs in patients. In addition, Glut 5 was expressed in both ER-positive (MCF-7) 
and -negative cell lines (MDA-MB-231), which mimic the early and late stage breast 
cancer respectively. It is now known that MDA-MB-231 cells have more Glut 5 than 
that of MCF-7 cells (Zamora-Leon et al., 1996). This means targeting Glut 5 by 
I 
antisense oligonucleotide can be used for treating all stages of breast cancer. 
Both in vitro and in vivo effect of Glut 5 antisense oligonucleotides will be 
investigated. For in vitro study, two human breast cancer cell lines will be used. 
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They are MCF-7 (ER-positive) and MDA-MB-231 (ER-negative). For in vivo study, 
MCF-7-cells-bearing nude mice will be used as animal model. The study will focus 
on the anti-proliferative effect, and assessment of the probable side effects caused by 
the antisense oligonucleotides. 
The ultimate goal of the project is to develop an effective approach to breast 
cancer treatment by using novel chemically modified antisense oligonucleotides 
against Glut 5. 
I 
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Materials and Methods 
2.1 Materials 
2.1.1 Cell Lines and Culture Medium 
Cell Lines: MCF-7 and MDA-MB-231 
The MCF-7 and MDA-MB-231 cell lines were purchased from American Type 
Culture collection (ATCC, Rockville, MD, USA). Both cell lines were cultured in 
complete RPMI 1640 medium (Gibco BRL, USA), which was supplemented with 
10% fetal bovine serum (v/v， FBS, Gibco BRL, USA) and 1% 
penicillin-streptomycin (v/v, PS, 10 OOOU/ml, Gibco BRL, USA). The cells were 
maintained at 37�C in a humidified atmosphere of 5% C02/95% air. 
Roswell Park Memorial Institute Tissue Culture Medium 1640 (RPMI 1640 
Medium, Gibco BRL, USA) 
RPMI 1640 medium was prepared by dissolving the powder which contains phenol 
red, L-glutamine and 0.5mM HEPES in IL of dHsO. The medium was supplemented 
with 2g of NaHC03. The pH was adjusted to 7.2. The medium was then filtered by 
0 .22/ /m bottle-top filter (Millipore). The complete RPMI 1640 medium was 
supplemented with 10% fetal bovine serum (v/v, FBS, Gibco BRL, USA) and 1% 
penicillin-streptomycin (v/v, PS, 10 OOOU/ml, Gibco BRL, USA). 
I 
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2.1.2 Buffers and Reagents 
Trypsin-EDTA Solution 
Trypsin-EDTA solution, containing 0.25% trypsin and 1 mM EDTA-tetrasodium in 
HBSS without Ca^^ and Mg2+，was purchased from Gibco BRL, USA. 
Trypan Blue Solution 
Trypan blue solution was purchased from Sigma Chemical Co. It contained 0.4% 
(w/v) trypan blue dissolved in 0.817% NaCl and 0.06% K2PO4. 
lOx Tris-Glycine 
lOx tris-glycine was prepared by dissolving 30.3g tris and 144g glycine in IL dHzO. 
The pH was adjusted to 8.3 and was stored at 4 � C . 
Normal Saline: 0.9% (w/v) Sodium Chloride (NaCl) 
0.9% NaCl was prepared by dissolving 9g of solid form of NaCl in IL of dHiO. It 
was stored at room temperature. 
Phosphate Buffered Saline (PBS) 
PBS was prepared by mixing 136mM NaCl, 2.7mM KCl, 1.5mM KH2PO4 and 8mM 
Na2P04. The chemicals are dissolved in ddHsO. The pH was adjusted to 7.4 and the 
solution was sterilized by autoclaving. It was stored at room temperature. 
Tris Buffered Saline (TBS) 
TBS was prepared by dissolving 12.114g Tris and 87.66g NaCl in IL dHzO. The pH 
was adjusted to 8 and stored at 4°C. 
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Tetrazolium Salt 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide 
(MTT, Sigma) Solution 
MTT was prepared by dissolving it in PBS at concentration of 5mg/ml. The solution 
was then filtered by a 0.22 {i m filter (Millipore). 
Tris-acetate (TAE) Buffer 
TAB was prepared as 5Ox concentrated stock solution by dissolving 242g Tris base, 
57.1ml glacial acetic acid and 100ml 0.5M EDTA (pH 8.0) in IL dHaO. 
Tris-EDTA(TE) Buffer 
TE was prepared by mixing lOmM Tris-Cl and ImM EDTA in dHjO. The pH was 
adjusted to 7.4. 
2.1.3 Reagents for Transfection 
Oligofectamine reagent (Invitrogen Co. Ltd.) 
Oligofectamine reagent was purchased from Invitrogen Co. Ltd. It was diluted with 
plain medium prior to use, according to the manufacturer's manual. It was stored at 
4 � C 
I 
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2.1.4 Reagents for D-[U^^C]-Fructose and 2-Deoxy-D-[l-^H] 
Glucose Uptake Assay 
D-fU^^CJ-Fructose and 2-Deoxy-D-[l-^H] Glucose 
D-[Ui4c]-fmctose (200/iCi/ml) and 2-deoxy-D-[l-^H] glucose (l.OmCi/ml) were 
purchased from Amersham Biosciences Ltd. They were stored at -20°C and 4°C 
respectively. 
2.1.5 Reagents for ATP Assay 
Intracellular ATP concentration was detected by using Bioluminesent 
somatic cell ATP assay kit, which was purchased from Sigma Chemical Co. This kit 
employed for the bioluminescent determination of the ATP released from a 
suspension of viable somatic cells: 
FLSAR 
Intracellular ATP > Free ATP 
Firefly Luciferase 
Free ATP + Luciferin ^ �Adenyl-luciferin + PPi 
Mg2+ 
Adenly-luciferin + O2 ^ Oxyluciferin + AMP + CO2 + Light 
The light emitted is proportional to the ATP present. 
‘ The kit contains ATP assay mix, ATP assay mix dilution buffer, lOX 
I 
somatic cell ATP releasing agent (FLSAR) and ATP standard (0.9mg). ATP assay 
mix should be dissolved in 5ml of autoclaved 啦。，and diluted for 25 folds with 
ATP assay mix dilution buffer. The ATP assay mix dilution buffer should be 
dissolved in 50ml of autoclaved 啦。be fo re use. The kit was stored at -20°C. 
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2.1.6 Reagents for RT-PCR 
2.1.6.1 Reagents for RNA Extraction 
TriZOL Reagent (Invitrogen Co. Ltd.) 
Trizol reagent was purchased from Invitrogen Co. Ltd. It was stored at 4°C for 
optimal performance. 
Chloroform 
Chloroform was purchased from BDH Laboratory Supplies, UK. It was stored at 
room temperature and in a flammable liquid safety cabinet. 
Isopropanol 
Isopropanol was purchased from BDH Laboratory Supplies, UK. It was stored at 
room temperature and in a flammable liquid safety cabinet. 
DEPC-treated Double Distilled Water (0.1%) 
DEPC-treated double distilled water was prepared by mixing 1ml of diethyl 
pyrocarbonate (DEPC, purchased from Sigma Chemical Co.) to IL of ddHiO in a 
fume hood and was stirred overnight to destroy RNase. It was then autoclaved to 
destroy DEPC. 
2.1.6.2 Reagents for Reverse Transcription 
ThermoscriptTM RT-PCR System for l'*-strand cDNA Synthesis Kit (Invitrogen 
Co. Ltd) 
Thermoscript ™ RT-PCR system for 1''-strand cDNA synthesis kit was purchased 
from Invitrogen Co. Ltd. This kit contains oligo dT ( 0 . 5 ！ f i \ \ lOX RT buffer 
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(200mM Tris-HCl (pH 8.4)，500mM KCl), O.IM DTT, lOmM dNTP mix, 
Thermoscript ™ RT(50U/ fi 1)，RNase ™ OUT recombinant ribonuclease inhibitor 
(40U/ li 1) and E. coli RNase H (2U/ fi 1). 
Taq polymerase (5000U/ml) 
Taq polymerase was purchased from Amersham Biosciences Ltd. It is a 
single-subunit enzyme purified from the thermophilic bacterium Thermus aquaticus. 
The assay condition was according to the manufacturer's manual. It was stored at 
-20 oc. 
2.1.6.3 Reagents for Gel Electrophoresis 
1% Agarose Gel (w/v) 
1% agarose gel was prepared by dissolving Ig agarose (Sigma Chemical Co.) in 
100ml TAE. It was boiled until the agarose was melted. The gel was cooled down to 
about 50°C and 10 1 of ethidium bromide (Amersham Biosciences Ltd.) was added. 
It was then poured into a cast gel system. 
6x DNA Loading Dye 
6x DNA loading dye was prepared by mixing 0.25% bromophenol blue (v/v), 0.25% 
xylene cyanol FF (v/v) and 30% glycerol (v/v) in dH20. 
I 
100 Base-Pair DNA Marker 
100 Base-Pair DNA Marker was prepared by mixing 3 {i\ of 1 / /g / /z 1 of the 100 
base-pair DNA marker (Amersham Biosciences Ltd.), 4 / /1 of 6x DNA loading dye 
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and 5 fi 1 autoclaved dHzO. 
QIAquick Gel Extraction Kit (Qiagen) 
QIAquick gel extraction kit was used for purification of cDNA in the agarose gel. 
The kit contains QIAquick spin columns, buffer QG, buffer PE, buffer EB，and 
collection tube. 40ml of absolute ethanol should be added to buffer PE before use. It 
was stored at room temperature. 
2.1.7 Reagents for Real-Time PGR 
TaqMan® Universal PGR Master Mix (Applied Biosystems HK Ltd.) 
TaqMan universal PGR master mix was purchased from Applied Biosystems HK Ltd. 
and contained AmpliTaq Gold® DNA Polymerase, AmpErase® UNG^ dNTPs with 
dUTP，Passive Reference I，and optimized buffer components. It was stored at 4°C. 
Assays-on-Demand™ 18S rRNA Gene Expression (Applied Biosystems HK 
Ltd.) 
Assays-on-Demand™ 18S rRNA gene expression was purchased from Applied 
Biosystems HK Ltd. It is the primers for 18S rRNA and labeled with a fluorescence 
dye "VIC". It was stored at -20°C. 
Assays-on-Demand™ Glut 5 Gene Expression (Applied Biosystems HK Ltd.) 
Assays-on-Demand™ Glut 5 gene expression that was purchased from Applied 
Biosystems HK Ltd. It contains the primers for Glut 5 labeled with a fluorescence 
dye “FAM”. It was stored at -20°C. 
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2.1.8 Reagents and Chemicals for Western Blotting 
2.1.8.1 Reagents for Protein Extraction 
Protein Lysis Buffer 
Lysis buffer was prepared by mixing 21|ig/ml aprotinin, 5/ /g/ml leupeptin, 5mM 
MgCl2, ImM PMSF, 1% SDS, ImM sodium meta-vanadate and lOmM tris buffer 
(pH 7.4) in PBS. It was stored at room temperature. 
Protein Standard (2mg/ml) 
Protein standard was prepared by dissolving 0.002g bovine serum albumin (BS) in 
1ml dH20. It was stored at -20°C. 
Bicinchoninic acid (BCA) solution (Sigma Chemical Co.) 
BCA solution was purchased from Sigma Chemical Co. and was stored at room 
temperature. 
ReagentB 
Reagent B was prepared by dissolving 4g of CUSO4-5H2O in 100ml dHsO. It was 
stored at room temperature. Mixture of BCA solution and reagent B should be 
freshly prepared each time. 
2.1.8.2 Reagents for SDS-PAGE 
10% Ammonium Persulfate (APS) 
APS was prepared by dissolving Ig ammonium persulfate in 10ml dHsO. It was 
stored at -20®C. 
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4x Lower Gel Buffer 
4x lower gel buffer was prepared by dissolving 181.6g Tris and 4g SDS in IL of 
dHzO. The pH was adjusted to 8.8 and it was stored at room temperature. 
4x Upper Gel Buffer 
4x upper gel buffer was prepared by dissolving 60.6g Tris and 4g SDS in IL of 
dH20. The pH was adjusted to 8.8 and it was stored at room temperature. 
12.5% Separating Gel for SDS-PAGE 
12.5% separating gel was prepared by mixing 1.0825 ml of dHzO, 1.6675 ml of 30% 
acrylamide, 1ml of 4X upper gel buffer, 4.65 fi 1 of TEMED and 20 /i 1 of 10% APS. 
Mixture should be freshly prepared for each experiment. 
4.5% Stacking Gel for SDS-PAGE 
4.5% stacking gel was prepared by mixing 1.2ml of dH20, 0.3ml of 30% acrylamide, 
0.5ml 4X lower gel buffer, 2.65 fi 1 of TEMED and 15/zl of 10% APS. Mixture 
should be freshly prepared for each experiment. 
2x SDS Loading Dye 
2x SDS loading dye was prepared by dissolving 2% (w/v) SDS, 10% sucrose, 
0.002% bromophenol blue and 62.5mM Tris in dHzO. The pH was adjusted to 6.8. 
Then the loading buffer was supplemented with 5% (v/v) 2-mercaptoethanol and 
stored at 4°C. 
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lOx SDS Running Buffer 
lOx SDS running buffer was prepared by dissolving 30.3g Tris, 144g glycine and 
lOg SDS in ILofdHzO. 
Rainbow™ Coloured Protein Molecular Weight Marker 
Rainbow™ coloured protein molecular weight marker was purchased from 
Amersham Biosciences Ltd. 
Polyvinylidene Difluoride (PVDF) Western Blotting Membrane 
PVDF membrane with a pore size of 0.45 |Lim was purchased from Millipore 
corporation. 
Electroblotting Buffer 
Electroblotting buffer was prepared by mixing 66.7ml of lOx Tris-glycine, 100ml 
methanol and 500ml of d H � � . 
Tris-Buffered Saline with 0.1% Tween-20 (TEST) 
Tris-Buffered Saline with 0.1% Tween-20 (TBST) was prepared by mixing 1ml of 
Tween-20 in ILTBS. 
Blocking Solution 
) 
Blocking solution was prepared by dissolving Ig of non-fat milk powder in 10ml of 
TBST. It was stored at 
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Primary and Secondary Antibodies 
The primary antibodies included mouse monoclonal anti-human P-actin and rabbit 
anti-human Glut 5 were purchased from Sigma and Research Diagnostics 
respectively. They were stored at -20�C. The secondary antibodies included 
anti-mouse IgM and goat anti-rabbit IgG HRP were purchased from Pharmigen and 
Santa Cruz Biotechnology Inc. respectively. They were stored at 4°C. 
Enhanced Chemiluminescence (ECL) Assay 
Enhanced chemiluminescence (ECL) assay kit was purchased from Amersham 
Biosciences Ltd. It was stored at 4°C. 
2.1.9 Reagents for Flow Cytometry 
TACSTM Annexin V Kits (Trevigen, Inc.) 
TAGS™ Annexin V Kits was purchased from Trevigen, Inc. The kit contains 
Annexin V-FITC, lOX Binding Buffer and propidium iodide. It was stored at 4°C. 
Propidium Iodide (PI) 
Propidium iodide was purchased from Sigma Chemical Co. It was reconstituted in 
PBS (2mg/ml). 
^bonuclease A (RNase A) 
Ribonuclease A (RNase A) was purchased from Sigma Chemical Co. It was 
dissolved in TE buffer (5mg/ml, pH 7.4). 
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2.1.10/w Vivo Study 
Animal Model: Balb/c Nude Mice 
Female nude mice aged 4-6 weeks were used as animal models for in vivo study. The 
mice were bred at the Laboratory Animal Services Center of The Chinese University 
of Hong Kong under pathogen-free condition. 
Sodium Pentobarbital Solution 
Sodium pentobarbital solution was prepared by dissolving 25mg of sodium 
pentobarbital in 1 ml of sterile PBS. It was stored at 4°C. 
Heparin Solution 
Heparin solution was prepared by dissolving 50 units of heparin in 1 ml of sterile 
PBS. It was stored at 4°C. 
Antisense Oligonucleotides 
AS 2 (Sequence: 5' ATG TGG CGA CTC TGC 3，) and its sense sequence (5' GCA 
GAG TCG CCA CAT 3') were used. 
) 
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2.2 Methods 
2.2.1 Oligonucleotide Design 
In this project, 5 oligonucleotide sequences with 15 base pairs were 
designed. One of them is a sense sequence and the others are antisense. Sense 
sequence is used to illustrate the non-specific effect. They are all complementary to 
human glucose transporter 5 cDNA sequence (Fig.2.1). The sequence and the region 
of the antisense or sense oligonucleotides are shown in table 2.1. The selected 
sequences were checked against their specificity to Glut 5 by using a program called 
“Blast，，in NCBI. The website is http://www.ncbi.nlm.nih.gov. In order to increase 
the stability, the sequences designed were then modified to 
phosphorthioated-oligonuclotide, with a sulfur ion replaced the oxygen ion in the 
phosphate group, as mentioned in section 1.3.4，fig. 1.8. 
I 
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1 cttctctctc cattcagtgc acgcgttact ttggctaaaa ggaggtgagc ggcactctgc 
61 ccttccagag caagcatgga gcaacaggat cagagcatga aggaagggag gctgacgctt 
121 gtgcttgccc tggcaaccct gatagctgcc tttgggtcat ccttccagta tgggtacaac 
181 gtggctgctg tcaactcccc agcactgctc atgcaacaat tttacaatga gacttactat 
241 ggtaggaccg gtgaattcat ggaagacttc cccttgacgt tgctgtggtc tgtaaccgtg 
301 tccatgtttc catttggagg gtttatcgga tccctcctgg tcggcccctt ggtgaataaa 
361 tttggcagaa aaggggcctt gctgttcaac aacatatttt ctatcgtgcc tgcgatctta 
421 atgggatgca gcagagtcgc cacatcattt gagcttatca ttatttccag acttttggtg 
481 ggaatatgtg caggtgtatc ttccaacgtg gtccccatgt acttagggga gctggcccct 
541 aaaaacctgc ggggggctct cggggtggtg ccccagctct tcatcactgt tggcatcctt 
601 gtggcccaga tctttggtct tcggaatctc cttgcaaacg tagatggctg gccgatcctg 
661 ctggggctga ccggggtccc cgcggcgctg cagctccttc tgctgccctt cttccccgag 
721 agccccaggt acctgctgat tcagaagaaa gacgaagcgg ccgccaagaa agccctacag 
781 acgctgcgcg gctgggactc tgtggacagg gaggtggccg agatccggca ggaggatgag 
841 gcagagaagg ccgcgggctt catctccgtg ctgaagctgt tccggatgcg ctcgctgcgc 
901 tggcagctgc tgtccatcat cgtcctcatg ggcggccagc agctgtcggg cgtcaacgct 
961 atctactact acgcggacca gatctacctg agcgccggcg tgccggagga gcacgtgcag 
1021 tacgtgacgg ccggcaccgg ggccgtgaac gtggtcatga ccttctgcgc cgtgttcgtg 
1081 gtggagctcc tgggtcggag gctgctgctg ctgctgggct tctccatctg cctcatagcc 
1141 tgctgcgtgc tcactgcagc tctggcactg caggacacag tgtcctggat gccatacatc 
1201 agcatcgtct gtgtcatctc ctacgtcata ggacatgccc tcgggcccag tcccataccc 
1261 gcgctgctca tcactgagat cttcctgcag tcctctcggc catctgcctt catggtgggg 
1321 ggcagtgtgc actggctctc caacttcacc gtgggcttga tcttcccgtt catccaggag 
1381 ggcctcggcc cgtacagctt cattgtcttc gccgtgatct gcctcctcac caccatctac 
1441 atcttcttga ttgtcccgga gaccaaggcc aagacgttca tagagatcaa ccagattttc 
1501 accaagatga ataaggtgtc tgaagtgtac ccggaaaagg aggaactgaa agagcttcca 
1561 cctgtcactt cggaacagtg actctggaga ggaagccagt ggagctggtc tgccaggggc 
1621 ttcccacttt ggcttatttt tctgacttct agctgtctgt gaatatccag aaataaaaca 
1681 actctgatgt ggaatgcagt cctcatctcc agcctcccca ccccagtggg aactgtgcaa 
1741 agggctgcct tgctgttctt gaagctgggc tgtctctctc catgttggcc tgtcaccaga 
1801 cccgagtcaa ttaaacagct ggtcctccac tttgctggtt cagccttcgt gtggctcctg 
1861 gtaacgtggc tccaccttga tgggtcaacc tttgtgtggc tcctggtaac ataacaacaa 
1921 cagttactat agtggtgaga tggaaggaat caaattttgc cagagaaact aactcggtgg 
1981 ccccaacagg tcttccgggg ccatgggcat ttgtttagag ccaaattcat cctcttacca 
2041 gatccttttc cagaaatacc tgtctaggaa ggtgtgatgt cagaaacaat gacatccaga 
2101 aagctgagga acaggttcct gtggagacac tgagtcagaa ttcttcatcc aaattatttt 
2161 gttagtggaa aatggaattg cttctgtgta gtcaataaaa tgaacctgat cacttttc 
Figure 2.1 
Glut 5 mRNA sequence. The complementary sequences of AS 1 to AS 4 were 
in bold fonts. 
I 
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Table 2.1 
The sequences and the regions of the antisense or sense oligonucleotides. They are 
named as S, AS 1 to AS 4. They can hybridize to different regions of the Glut 5 
cDNA sequence. 
Name ~ " “ R e g i o n S e q u e n c e (5'-> 3，) 
Sense 70-84 GCAAGC ATG GAG CAA 
(S) 
Antisense 1 70-84 TTG CTC CAT GCT TGC 
(AS 1) 
Antisense 2 431-445 ATG TGG CGA CTC TGC 
(AS 2) 
Antisense 3 ~ 1 2 2 1 - 1 2 3 5 TGT CCTATGACGTAG 
(AS 3) 
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2.2.2 Trypan Blue Exclusion Assay 
0.4% trypan blue solution was mixed with 10/zl of cell suspension. Then, 
10//1 was transferred to the hemacytometer. The viable cells, which were not 
stained, were counted in a square of hemacytometer. The cell concentration (cells/ml) 
was calculated as follows: 
Cells per ml = Number of cell x 10^ x Dilution factor 
2.2.3 Transfection 
The cationic lipid, oligofectamine reagent (Invitrogen Co. Ltd.) was used 
as carrier to deliver the antisense oligonucleotides into the cells. The procedure of 
transfection was performed according to the manufacturer's manual. Briefly, 
oligofectamine reagent was first diluted with plain RPMI and was allowed to stand 
at room temperature for 5 minutes. In this 5 minutes, the oligonucleotides were 
diluted with serum free RPMI. Then the diluted oligofectamine and oligonucleotides 
were mixed and incubated for 15 minutes at room temperature to allow the 
formation of lipid-oligonucleotide complex. During the incubation period, the 
medium in the culture plate was replaced by serum free RPMI to facilitate 
transfection. After 15 minutes, the complexes were added to the cells and incubated 
for 4 hours at 37�C. By the end of incubation, serum was added to increase the 
volume. Two or three days later, the plate could be used for assaying. 
) 
2.2.4 MTT assay 
8x103 cells per well were seeded onto a 96-well plate in 100//I RPMI 
supplemented with 10% FBS (v/v). At the time of seeding and during transfection, 
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no antibiotics were used. This can help cell growth and allow transfection with 
rinsing the cells if they are to be transfected in the presence of serum. After 24 hours, 
transfection could be carried out. After 48 or 72 hours, the medium in each well was 
removed and each well was washed with PBS once. Then, 30 //1 of MTT solution 
(5mg/ml) was added to each well and the plate was incubated at 37°C for 2 hours. 
After incubation, the MTT was discarded and 100//I DMSO was added to dissolve 
the crystals and further incubated for 30 minutes at room temperature. The 
absorbance at 540nm was then measured by an ELISA plate reader (BIO-RAD). The 
blank was set using 100/zl of DMSO only. 
2.2.5 D-[U^^C]-Fructose and 2-Deoxy-D-[l-^H] Glucose 
Uptake Assay 
4x104 cells per well were seeded onto a 24-well plate in 500 RPMI 
supplemented with 10% FBS (v/v). One day later, transfection could be carried out. 
After 48 or 72 hours, -fructose and 2-deoxy-D-[l-^H] glucose uptake assay 
can be performed. The procedure in Wu et aL (1998) was followed, with 
modifications. Firstly, the medium in each well was discarded and each well was 
washed with PBS once. Then 0.5ml PBS (0.5ml glucose-free RPMI, Gibco BRL, 
USA, for glucose uptake assay) was added to each well and incubated at 37 °C for 1 
hour to release the endogenous fructose or glucose. After incubation, O.lmM 
fructose and 0.5/zCi D^U'^^C]-fructose (O.lmM 2-deoxy-glucose and 0.5/zCi 
2-deoxy-D-[l-^H] glucose for glucose uptake assay, Amersham Biosciences Ltd.) in 
1ml PBS was added to each well and incubated at 37 °C for 15 minutes. The PBS 
was discarded and each well was washed with lOmM fructose (lOmM 
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deoxy-glucose) in normal saline twice. After that, 100 /z 1 0.5mM NaOH was added 
to each well to lyse the cell and the plate was shaken at room temperature for 15 
minutes. Finally, 100/zl 0.5mM HCl was added for neutralization. Volume of 
120/zl was added to the scintillation vial containing 4ml scintillation fluid for 
counting and 20 fi 1 was used for protein concentration determination using BCA 
method. 
Count per minute (cpm) 
Amount of fructose (glucose) uptake = 
Amount of protein ( i i g) 
(cpm/以 g) 
2.2.6 Detection of Intracellular ATP Concentration 
Intracelluar ATP concentration was detected by using Bioluminesent 
somatic cell ATP assay kit (Sigma Chemical Co.). 8x10"^  cells were seeded in a 
well of a 12-well culture plate. One day later, transfection can be carried out. 72 
hours later, the medium in each well was removed and washed with PBS twice. 
0.3ml IX somatic cell ATP releasing agent was added to each well and the plate was 
shaken by orbital shaker (KikaLabotechnik) in 300 mot/min for 3 minutes. At the 
same time, 0.1ml of ATP assay mix solution was added to a reaction vial and 
allowed to stand at room temperature for 3 minutes to hydrolyze the endogenous 
ATP. Then, 0.1ml of cell lysate or ATP standard (or dHzO as blank) was transferred 
to the reaction vial, and the amount of light emitted (L) was measured immediately 
I 
with a luminometer (Lumat LB 9501, Berthold). Standard curve of ATP 
concentration should be plotted against the L (Fig. 2.2). The amount of protein in the 
lysate was also measured by BCA method. 
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A T P Standard curve 
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Figure 2.2 
ATP standard curve. The equation of the trend line is for calculation of the ATP 
concentration in samples. The total ATP per/zg of protein can be calculated as 
follows: 
[ATP] (mg/ml) = L of sample/5 x 10^ 
[ATP]mg/ml x 0.3ml 
Total ATP per mg of protein = 
Amount of protein (mg) 
) 
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2.2.7 Reverse Transcription- Polymerase Chain Reaction 
(RT-PCR) 
2.2.7.1 RNA Extraction by TRIzol Reagent (Invitrogen Co. Ltd.) 
1.6x10^ cells per well were seeded onto 6-well plate in 2ml RPMI 
supplemented with 10% FBS (v/v). 1 day later, transfection could be carried out. 
After 72 hours, the medium was removed and washed each well with PBS once. 1ml 
of TRIzol reagent was added to each well and the cells were lysed by pipetting up 
and down for several times. The lysate was transferred to a clean microflige tube and 
was kept at 4 to prevent rapid degradation of RNA. Then, 200 /z 1 of chloroform 
was added to each tube and the tube was vortex vigorously for 15 seconds. The tube 
was then centrifUged at 13 600 x g for 15 minutes at 4°C. After centrifugation, the 
upper colourless aqueous phase contains RNA and was poured into a new clean 
microfuge tube. 500 {i 1 of isopropanol was added to the tube and incubated at -20 °C 
for more than 1 hour. After incubation, the sample was centrifiiged at 13 600 x g for 
15 minutes at 4°C. The supernatant was removed and 1ml of ice-cold 75% ethanol 
was added to wash the pellet. The 75% ethanol was then removed and 20/ / I of 
DEPC H2O was added to dissolve the RNA. RNA should be kept at -80 
2.2.7.2 Determination of RNA Concentration 
The RNA concentration can be measured spectrophotometrically, at 
260nm and 280nm. The spectrophotometric assessment of RNA concentration is 
based on the strong absorption of light at 260nm of RNA. The absorption was 
measured at the peak of the RNA spectra and concentrations could be calculated by 
using the following equations: * [RNA] ( j i g/ml) = 40/(1/ O . D . 2 6 0 ) . 
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The purity of the RNA can be reflected by the concentration of protein in 
the sample. This is achieved by measuring absorbance at 280nm. A pure sample of 
RNA should have a ratio of absorbance at 260/280nm exceeding 1.75 for further 
analytical purposes. 
‘ * For dsDNA: [DNA] ( / / g /ml ) = 50/(1/ O .D.260) 
2.2.7.3 Reverse Transcription 
Reverse transcription was performed by using the Thermoscript ™ 
RT-PCR system for l®^-strand cDNA synthesis kit. The procedure in manufacturer's 
manual was followed. Briefly, 1 / i l of oligo dT, 2 //1 of lOmM dNTP mix, 2 / / g of 
RNA, and DEPC H2O were mixed to give the volume of 12/zl in total. The RNA 
and primer were denatured at 65�C for 5 minutes and chilled in ice. Then, 4 / i l o f 5 X 
cDNA synthesis buffer, 1 以 1 of 0.1 M DTT, 1//1 of RNaseOut™ (40U/ /d)，1 以 1 of 
DEPC H2O and 1 /i 1 of Thermoscript™ RT (15U//Z1) were added to each tube. The 
sample was then transferred to a thermocycler (ABI) preheated to 50 for 1 hour 
and the reaction was terminated by incubating at 85 for 5 minutes. Finally, 1 //1 of 
RNase H was added and further incubated at 37 for 20 minutes. The product, 
cDNA, can be stored at -20 
> 
2.2.7.4 Polymerase Chain Reaction (PCR) 
Amplification of target genes from the cDNA was performed using the 
primers in table 2.2. The reagents used in PCR was listed in table 2.3. 
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Table 2.2 
Sequences of primers used in PCR. These sequences were checked by the "Blast" 
program o f N C B I for homology. 
Genes Direction Primer sequence Product size 
/3-actin Forward 5，CCT CGC CTT TGC CGA TCC 3 ’ VOOb.p. 
Reverse ^ ’ GGA TCT TCA TGA GGT AGT CAG TC 3， 
~ G l u t 5 Forward 5’ CGT GCC TGC GAT CTT AAT GGG 3， 581b.p. 
Reverse ^, 丁AG ATC TGG TCC GCG TAG TAG 3， 
I 
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Table 2.3 
Volume of reagents used in PGR. 
Reagent Volume added ( f i 1) 
"^NA 5 
" T o X P C R buffer 2.5 
~Z5mM dNTP 2.5 
2.5mM Forward primer ^  
2.5mM Reverse primer ^  
High grade DMSO 1.5 
Tag polymerase ^  




Materials and Methods 
The reaction mix (Table 2.3) was then undergone PGR by PGR machine 
(Applied Biosystem). Thermocycling was carried out as follows: 
For /3 -actin, For Glut 5, 
94°C for 5 minutes 94�C for 5 minute 
940c for 1 minute � 94°C for 1 minute � 
63°C for 40 seconds I Repeat for 28 52°C for 50 seconds I Repeat for 45 
cycles cycles 
72 for 40 seconds 7 2 � C for 50 seconds 
J J 
72 for 10 minutes 72 for 10 minutes 
Amplification products were stored at -20°C and then resolved in 1% 
agarose gel. 
2.2.8 Real-Time PGR 
RNA extraction, determination of RNA concentration and reverse 
transcription were followed the procedure described in section 2.2.7.1-2.2.7.3. 
Amplification of target genes from the cDNA was performed with reagents listed in 
table 2.4. Samples were loaded in triplicate. Real-time PGR was run in ABI 
PRISM® 7000 Sequence Detection System. The reaction mix (Table 2.4) was then 
undergone PGR by ABI PRISM® 7700 Sequence Detection System (Applied 
Biosystem). Thermocycling was carried out as follows: 
Stage 1: 50°C for 2 minutes 
‘ � Stage 2: 95 for 10 minutes 
Stage 3: 95°C for 15 s e c o n d s � 
I Repeat for 50 cycles 
60°C for 1 minute 
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Table 2.4 
Volume of reagents for real-time PGR. 
Reagent Volume added (/zl) 
" ^ N A 1 
TaqMan® Universal PGR 5 
Master Mix  
Assays-on-Demand"^ 0.5 
Glut 5 Gene Expression  
Assays-on-DemancfM I8s ^ 
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2.2.8.1 Analysis of the Real-Time PCR Data 
The endpoint of real time PCR analysis is the threshold cycle (CT). 
Threshold cycle (Op) is the cycle number at which the fluorescence emission 
exceeds the fixed threshold. The initial amount of target template is inversely 
proportional to the Ct. Ct was determined by using the computer program 
"Sequence Detection Systems, Version 1.9, by Applied Biosystem". The expression 
level of the target gene which is represented by "Mean fold change" can be 
calculated as follows: 
Mean fold change = 2.八 
Where AACT = A C j of target gene of sample - A C T of target gene control 
ACT = CT of target gene - CT of 18S rRNA 
(Livak and Schmittgen, 2001). 
Mean fold change of target gene represents the amount of target gene. Mean 
fold change of negative control was set to be 1. For down-regulation of target gene, 
the mean fold change is ranged from 0-1; for up-regulation of target gene, the mean 
I 
fold change is greater than 1. 
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2.2.9 Western Blot Analysis 
2.2.9.1 Protein Extraction 
8 X 104 cells were seeded on 100mm culture dish. 1 day later, transfection 
can be carried out. 72 hours later, cells were collected and were washed twice with 
PBS. 100 /i 1 of lysis buffer was added and allowed to stand on ice for 3 hours. Then, 
samples were boiled for 10 minutes and centrifUged at 13 600 x g for 10 minutes at 
4°C. Finally, the supernatant was collected and stored at -20°C. 
2.2.9.2 Protein Concentration Determination 
The protein concentration can be determined by bicinchoninic acid 
(BCA) protein assay. 1 of each sample was mixed with 9 ji 1 o f d H i O in a 96-well 
plate. Bovine serum albumin (BSA) was used to establish the protein standard curve. 
Both protein samples and BSA standard were done in triplicate. BCA reaction 
mixture was composed of BCA solution and reagent B in the ratio of 50:1. 200 [i 1 of 
BCA mixture was added to each well and incubated at 3 7 � C for 30 minutes. After 
incubation, the absorbance at 540 nm was measured by ELISA plate reader 
(Bio-Rad). Standard curve of protein amount was plotted against the OD540nm (Fig. 
2.3)，and the amount of protein in the sample can be calculated by the equation of 
the trend line. 
58 
Materials and Methods 
Protein standard curve 
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Figure 2.3 
Protein standard curve. 2-10/zg of BSA was added to each well in 96 well plate. 
200 [11 of BCA mixture was added to each well and incubated at 2>TC for 30 
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2.2.9.3 Western Blotting 
SDS-PAGE 
The apparatus of 3D vertical electrophoresis system (Bio-Rad) was set 
according to manufacturer's manual. 12.5% polyacrylamide separating gel was set 
with 1.0825 ml of (IH2O，1.6675 ml of 30% acrylamide, 1ml of 4X upper gel buffer, 
4.65 fi 1 of TEMED and 20 / / I of 10% APS. 4.5% stacking gel was set with 1.2ml of 
dH20, 0.3ml of 30% acrylamide, 0.5ml 4X lower gel buffer, 2.65 fi 1 of TEMED and 
15/zl of 10% APS. 
According to the BSA standard curve, equal amount of protein samples 
(25-40 fi g) were used for SDS-PAGE. Protein samples were mixed with equal 
volume of 2 X SDS loading dye and boiled for 10 minutes. Then samples were 
loaded to the well of the polyacrylamide gel with rainbow coloured protein 
molecular marker (Amersham Bioscience Ltd.). The gel was then run at 120V for 90 
minutes. The upper stacking gel was removed. 
Transfer of Protein to PVDF Membrane by Electroblotting 
Semi-Dry Electrophoretic Transfer Cell (semi-dry blotter, BioRad) was set 
referring to the steps in the manual. PVDF membrane (0.45 ji m) (Immobilon, 
Millipore) was used for electroblotting. The dry PVDF membrane was soaked in 
absolute methanol for re-hydration. The membrane was then put in E-blot buffer for 
a few seconds. Three pieces of Whatman 3mm papers were soaked in E-Blot 
buffer and put onto the platinum anode. The membrane was put onto the Whatman 
3mm papers followed by the acrylamide gel. Another 3 pieces of E-blot 
buffer-soaked 3mm paper were put onto the gel. The proteins were transferred at 
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constant current at 0.15A for 2 gels for 45 minutes. 
Probing Proteins with Antibodies 
After transfer of protein to the PVDF membrane, the membrane should be 
blocked with 10% non-fat milk (in TBS-T) at room temperature for 2 hours. Then, 
it was washed with TBS-T for 15 minutes for 3 times. Primary antibody, 0.6 {i 1 of 
mouse anti-human P-actin or 3 " 1 of rabbit anti-Glut 5 in 3ml 10% non-fat milk was 
added for probing at room temperature for 2 hours. After probing, the membrane 
was washed with TBS-T for 15 minutes for 3 times and probed with secondary 
antibody (conjugated with horseradish peroxidase) at room temperature for 1 hour. 
The membrane was washed again with TBS-T for 15 minutes for 3 times and it was 
ready for ECL detection. 
Enhanced Chemiluminescence (ECL) Assay 
ECL assay was used for detection of probed proteins. ECL detection 
reagent 1 and reagent 2 (Amersham) were mixed in the ratio of 1:1 and the 
membrane was immersed in the mixture for 90 seconds. Then the membrane was 
wrapped and put into the Hypersensitive film cassette (Amersham) followed by a 
Fuji Medical x-ray film (Super Rx, Fuji) in dark with various exposure time. The 
film was then developed by a film processor (M35 X-OMAT, Kodak). 
I 
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2.2.10 Flow Cytometry 
A computer program, WinMDI, was used for data analysis. 
2.2.10.1 Detection of Cell Cycle Pattern with PI 
4x10^ cells were seeded in a 60 mm culture dish with serum free RPMI to 
synchronize the cells. 1 day later, transfection can be carried out. 72 hours later, cells 
were harvested and washed with PBS. Cells were then fixed with 1 ml of 70% 
ethanol at 4°C overnight. After fixation, the cells were centrifuged at 300 x g for 5 
minutes to remove the ethanol. Cells were then resuspended in 0.46 ml freshly 
prepared propidium iodide solution containing propidium iodide (43 ng/ml) and 
RNase A (1 mg/ml) and incubated in dark at 37°C for 30 minutes. After incubation, 
the cells were analyzed by FACSort flow cytometer (Becton Dickinson). 
2.2.10.2 Detection of Apoptosis with Annexin V/PI 
The detection of apoptosis was performed by using TAGS™ Annexin 
V-FITC kit (Trevigen, Inc.). 4x1 O^  cells were seeded in a 60 mm culture dish. 1 day 
later, transfection could be carried out. 72 hours later, cells were harvested and 
washed with PBS. 5x10^ cells were used for the assay. 10/zl of lOX binding buffer, 
10//I of PI, \ jiX of Annexin V-FITC conjugate and 79 //1 of dHzO were added to a 
sample and incubated in the dark at room temperature for 15 minutes. After 
I 
incubation, 400/ / I of IX binding buffer was added to the sample and the sample 
was analyzed by FACSort flow cytometer (Becton Dickinson). 
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2.2.11 In Vivo Study 
2.2.11.1 Establishment of Tumor-Bearing Animal Model 
Female nude mice were used for investigating the in vivo effect of the 
antisense oligonucleotides against Glut 5. 1x10^ cells were inoculated 
subcutaneously (s.c.) into the anterior part of the nude mice and allowed to grow for 
5-10 days. The weight of the mice, size of tumor should be measured before 
treatment. Treatments were started when the tumor size reached about 4mm x 4mm 
X 3mm (~50mm^). 
2.2.11.2 Treatment Schedule 
The mice were divided into 3 groups, 10 mice per group, randomly. 
Groups included (1) PBS-Control group, (2) Sense-control group and (3) Antisense 
group. 
For sense and antisense group, 20mg/kg/day of oligonucleotides were 
injected s.c., adjacent to the tumor in each nude mice for 8 doses, every other day. 
For PBS-control group, 0.1ml of PBS was injected. The antisense oligonucleotides 
were administrated into the tumor-bearing mice s.c., with constant volume of 
0. Iml/mouse/injection. 
After 8 doses, the mice were sacrificed. The weight of the mice should be 
recorded. The mice were first anesthetized by intra-peritoneal (i.p.) injection of 
0.1ml pentobarbital. Then, the mice could be dissected and 0.5-0.8ml whole blood 
was withdrawn from the heart. The blood was transferred to a 1.5ml microfuge tube 
which contained 20/ /1 of heparin and was centrifuged at 1000 x g for 10 minutes at 
4°C. After centrifugation, the plasma was transferred to a clean microftige tube and 
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Stored at 4 until enzyme assay was performed. 
On the other hand, the tumor should be taken out and the volume was 
measured. The volume of tumor was calculated as follows: 
Volume of tumor (mm� )=Length (mm) x Width (mm) x Height (mm) 
The tumor was homogenized and then RNA or protein was extracted 
from the homogenate, following the procedure in section 2.2.9. 
2.2.11.3 Toxicity of Antisense Oligonucleotides 
To assess the toxicity of antisense oligonucleotides after treatment, 
plasma enzymes activities were measured. After the above treatment, the mice were 
sacrificed and plasma was collected. The activities of 4 plasma enzymes, creatine 
kinase (CK), lactate dehydrogenase (LDH), alanine transaminase (ALT) and 
aspartate transaminase (AST), were measured by enzymatic diagnostic kits (Sigma). 
Increased activities of CK and LDH indicate heart tissue damage. While the 
increases of ALT and AST indicate liver tissue damage. 
The procedures of measuring the enzymatic activities were according to the 
protocol of the enzymatic kits. Briefly, for measuring CK and LDH activities, 25 //1 
of plasma was mixed with 500 ml of CK or LDH reagent, respectively. The 
mixture was then incubated at 30°C for 3 minutes and 30 seconds for CK and LDH, 
respectively. The absorbance was measured at 340 nm by spectrophotometer 
(Beckman) for 2 minutes and 1 minute for CK and LDH, respectively at 30 seconds 
interval. For measuring AST and ALT, 100/ i l of plasma was mixed with 1 ml AST 
or ALT reagent and incubate at 37°C for 1 minute. Absorbance was measured at 340 
nm at 30 seconds interval for 2 minutes. 
64 
Materials and Methods 
The enzymatic activities were calculated as follows: 
Enzymatic activity (U/L) = (AA per min x TV x 1000)/ (6.22 x LP x SV) 
where AA per min = change in absorbance per minute at 340 nm 
TV = total reaction volume (ml) 
LP = light path 
6.22 = millimolar absorptivity of NADPH at 340 nm 
SV = sample volume 
1000 = conversion of units per ml to per liter 
thus, CK (U/L) = AA per min x 8200 
LDH (U/L) = AA per min x 3376 
AST (U/L) = AA per min x 1768 
ALT (U/L) = A A per min x 1768 
The mean value of the plasma enzymatic activities of the same group was then 









3.1 In Vitro Study 
3.1.1 Effect of Tamoxifen on the Growth of MCF-7 and 
MDA-MB-231 cells 
Tamoxifen is the most common anti-cancer drug for treating breast cancer. 
It has been used for more than 20 years. Tamoxifen works against the effects of 
estrogen on the breast cancer cells, i.e. anti-estrogen, and exerts it actions through 
the estrogen receptors (ER). Therefore, it is efficient to treat early stage, ER-positive 
breast cancer but not advanced stage, ER-negative, breast cancer. 
The cytotoxic effects of tamoxifen on MCF-7 cells and MDA-MB-231 cells 
were investigated using MTT assays (Fig. 3.1). After 48 or 72 hour incubation, the 
I C 5 0 of tamoxifen on MCF-7 cells were 15|iM and l2.5}xM respectively. For 
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The dose-response curve of tamoxifen on MCF-7 and MDA-MB-231 cells (Each 
point represents mean 土S.D.，n = 6). 
(A) Incubated for 48 hours (obtained from the thesis of Chan KK). 
(B) Incubated for 72 hours 
1x104 cells per well were seeded on 96-well plates. After 24 hours, lOOmM 
tamoxifen (in 100% EtOH) was diluted to certain concentrations with RPMI 1640 
medium supplemented with 10% FBS and 5% PS. 200 [i 1 of diluted tamoxifen was 




3.1.2 Cytotoxicity of Antisense Oligonucleotides against Glut 5 on 
MCF-7 cells and MDA-MB-231 cells by MTT Assay 
The cytotoxic effects of various concentrations of antisense oligonucleotides 
(AS), namely 200nM, 400nM, 600nM, 800nM and 1 /z M, AS 1 to AS 4, flanking 
different regions of the Glut 5 mRNA (Fig.3.2), were investigated by MTT assay. All 
AS caused cytotoxic effects after 72-hour of incubation on both cell lines in a dose 
dependent manner. AS 1，which is complementary to the start codon exhibited an 
I C 5 0 of 220nM on MCF-7 cells, while it gave 410nM on MDA-MB-231 cells (Fig. 
3.3). AS 2, which is complementary to the coding region near 5' end exhibited an 
I C 5 0 of 190nM on MCF-7 cells, while it exhibited 400nM on MDA-MB-231 cells 
(Fig. 3.4). AS 3，which is complementary to the coding region near 3' end, exhibited 
an I C 5 0 of 300nM on MCF-7 cells, while it exhibited 400nM on MDA-MB-231 cells 
(Fig. 3.5). AS 4, which is complementary to the stop codon exhibited an I C 5 0 of 
220nM on MCF-7 cells, while it exhibited 470nM on MDA-MB-231 cells (Fig. 3.6). 




1 cttctctctc cattcagtgc acgcgttact ttggctaaaa ggaggtgagc ggcactctgc 
61 ccttccagag caagcatgga gcaacaggat cagagcatga aggaagggag gctgacgctt 
121 gtgcttgccc tggcaaccct gatagctgcc tttgggtcat ccttccagta tgggtacaac 
181 gtggctgctg tcaactcccc agcactgctc atgcaacaat tttacaatga gacttactat 
241 ggtaggaccg gtgaattcat ggaagacttc cccttgacgt tgctgtggtc tgtaaccgtg 
301 tccatgtttc catttggagg gtttatcgga tccctcctgg tcggcccctt ggtgaataaa 
361 tttggcagaa aaggggcctt gctgttcaac aacatatttt ctatcgtgcc tgcgatctta 
421 atgggatgca gcagagtcgc cacatcattt gagcttatca ttatttccag acttttggtg 
481 ggaatatgtg caggtgtatc ttccaacgtg gtccccatgt acttagggga gctggcccct 
541 aaaaacctgc ggggggctct cggggtggtg ccccagctct tcatcactgt tggcatcctt 
601 gtggcccaga tctttggtct tcggaatctc cttgcaaacg tagatggctg gccgatcctg 
661 ctggggctga ccggggtccc cgcggcgctg cagctccttc tgctgccctt cttccccgag 
721 agccccaggt acctgctgat tcagaagaaa gacgaagcgg ccgccaagaa agccctacag 
781 acgctgcgcg gctgggactc tgtggacagg gaggtggccg agatccggca ggaggatgag 
841 gcagagaagg ccgcgggctt catctccgtg ctgaagctgt tccggatgcg ctcgctgcgc 
901 tggcagctgc tgtccatcat cgtcctcatg ggcggccagc agctgtcggg cgtcaacgct 
961 atctactact acgcggacca gatctacctg agcgccggcg tgccggagga gcacgtgcag 
1021 tacgtgacgg ccggcaccgg ggccgtgaac gtggtcatga ccttctgcgc cgtgttcgtg 
1081 gtggagctcc tgggtcggag gctgctgctg ctgctgggct tctccatctg cctcatagcc 
1141 tgctgcgtgc tcactgcagc tctggcactg caggacacag tgtcctggat gccatacatc 
1201 agcatcgtct gtgtcatctc ctacgtcata ggacatgccc tcgggcccag tcccataccc 
1261 gcgctgctca tcactgagat cttcctgcag tcctctcggc catctgcctt catggtgggg 
1321 ggcagtgtgc actggctctc caacttcacc gtgggcttga tcttcccgtt catccaggag 
1381 ggcctcggcc cgtacagctt cattgtcttc gccgtgatct gcctcctcac caccatctac 
1441 atcttcttga ttgtcccgga gaccaaggcc aagacgttca tagagatcaa ccagattttc 
1501 accaagatga ataaggtgtc tgaagtgtac ccggaaaagg aggaactgaa agagcttcca 
1561 cctgtcactt cggaacagtg actctggaga ggaagccagt ggagctggtc tgccaggggc 
1621 ttcccacttt ggcttatttt tctgacttct agctgtctgt gaatatccag aaataaaaca 
1681 actctgatgt ggaatgcagt cctcatctcc agcctcccca ccccagtggg aactgtgcaa 
1741 agggctgcct tgctgttctt gaagctgggc tgtctctctc catgttggcc tgtcaccaga 
1801 cccgagtcaa ttaaacagct ggtcctccac tttgctggtt cagccttcgt gtggctcctg 
1861 gtaacgtggc tccaccttga tgggtcaacc tttgtgtggc tcctggtaac ataacaacaa 
1921 cagttactat agtggtgaga tggaaggaat caaattttgc cagagaaact aactcggtgg 
1981 ccccaacagg tcttccgggg ccatgggcat ttgtttagag ccaaattcat cctcttacca 
2041 gatccttttc cagaaatacc tgtctaggaa ggtgtgatgt cagaaacaat gacatccaga 
2101 aagctgagga acaggttcct gtggagacac tgagtcagaa ttcttcatcc aaattatttt 
2161 gttagtggaa aatggaattg cttctgtgta gtcaataaaa tgaacctgat cacttttc 
Figure 3.2 
Glut 5 mRNA sequence. The complementary sequences of AS 1 to AS 4 were 
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Figure 3.3 
Cytotoxicity of AS 1 on (A) MCF-7 cells, (B) MDA-MB-231 cells. 
7x10 cells were seeded on each well of 96-well plate. On the next day, transfections 
of lOOnM to 1.2|iM of AS 1, with oligofectamine, were carried out. After 72 hours 
incubation, MTT assays were done. The value for untreated control cells was set at 
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Figure 3.4 
Cytotoxicity of AS 2 on (A) MCF-7 cells, (B) MDA-MB-231 cells. 
7x10^ cells were seeded on each well of 96-well plate. On the next day, transfections 
of lOOnM to 1.2iiM of AS 2, with oligofectamine, were carried out. After 72 hours 
incubation, MTT assays were done. The value for untreated control cells was set at 
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Figure 3.5 
Cytotoxicity of AS 3 on (A) MCF-7 cells, (B) MDA-MB-231 cells. 
7x10^ cells were seeded on each well of 96-well plate. On the next day, transfections 
of lOOnM to 1.2|xM of AS 3，with oligofectamine, were carried out. After 72 hours 
incubation, MTT assays were done. The value for untreated control cells was set at 
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Cytotoxicity of AS 4 on (A) MCF-7 cells, (B) MDA-MB-231 cells. 
7x10^ cells were seeded on each well of 96-well plate. On the next day, transfections 
of 1 OOnM to 1.2\iM of AS 4，with oligofectamine, were carried out. After 72 hours 
incubation, MTT assays were done. The value for untreated control cells was set at 




IC5o(nM) of AS 1 to AS 4 on MCF-7 cells and MDA-MB-231 cells. The I C 5 0 values 
were obtained from the MTT assay, after 72-hour incubations. 
ICso(nM) 
Cell line MCF-7 cells MDA-MB-231 cells 
AS 1 220 410 
AS 2 190 400 
AS 3 300 400 




3.1.3 Effect of Antisense Oligonucleotides against Glut 5 on Fructose 
and Glucose Uptake of MCF-7 Cells and MDA-MB-231 
Cells by D-[U^^C]-Fructose and 2-Deoxy-D-[l-^H] Glucose 
Uptake Assay 
Glut 5 is responsible for transport fructose in the intestine and sperm. In the 
previous part, it was found that AS against Glut 5 caused a cytotoxic effect in breast 
cancer cell lines in a dose dependent manner. We hypothesized that AS against Glut 
5 can down-regulate the mRNA and protein expression of the target gene and thus 
decrease the fructose uptake in the cells. Therefore, -fructose and 
2-deoxy-D-[l-^H] glucose uptake assays were performed to test whether the fructose 
and glucose uptake level decrease after AS treatment in both cell lines. The 
procedure was described in section 2.2.5. 
For MCF-7 cells, after treatment of AS, the fructose uptake was decreased 
when compared with that of the negative control and the sense control, after 72 
hours of transfection (Fig. 3.7A). For MDA-MB-231 cells, a similar result was 
obtained (Fig. 3.7B). 
> 
2-deoxy-D-[l-^H] glucose uptake assay was also done to test whether the 
AS affect glucose transport in the cancer cells, followed the procedure described in 
Chan et al. (1999). It can be also used to test the specificity of the AS. If the AS only 
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hybridized only to Glut 5, the glucose uptake level should not be decreased, as Glut 
5 is a fructose transporter, rather than a glucose transporter. It is more specific and 
effective in transporting fructose (Tatibouet et al., 2000). For MCF-7 cells, after 
treatment of AS, the glucose uptake was not reduced significantly, when compared 
with the negative control and the sense control, after 72 hours of transfection (Fig. 
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Figure 3.7 
Effect of AS on -fructose on (A) MCF-7 cells; (B) MDA-MB-231 cells. 
The procedure was described in section 2.2.5. Data shown were mean 士 S.D.，n = 4. 
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Figure 3.8 
Effect of AS on 2-deoxy-D-[l-^H] glucose uptake on (A) MCF-7 cells; (B) 
MDA-MB-231 cells. The procedure was described in section 2.2.5. Data shown 




3.1.4 Effect of Antisense Oligonucleotides against Glut 5 on 
Intracellular ATP Content of MCF-7 Cells and MDA-MB-231 
Cells by ATP Assay 
As mentioned above, Glut 5 is highly expressed in breast cancer cells, but 
absent in normal breast cells (Zamora-Leon et al, 1996). This finding indicated that 
breast cancer cells may have a specialized capacity to transport fructose which is a 
rare metabolic substrate to be used by only a few human tissues. If fructose is the 
metabolic substrate for the breast cancer cells, the ATP content in the cells should be 
changed upon the inhibition of fructose uptake. Therefore, intracellular ATP assay 
was done to investigate the effect of AS on the breast cancer cells. 
The intracellular ATP level was measured by Bioluminesent somatic cell 
ATP assay kit (Sigma Chemical Co.). The procedure was described in section 2.2.6. 
Standard curve of ATP concentration should be plotted against the light emitted (L) 
(Fig. 2.2). The amount of protein in the lysate was also measured by the BCA 
method. 
For MCF-7 cells, after treatment of AS, the intracellular ATP content was 
I 
reduced significantly, from 50-60%, when compared with the negative control and 
the sense control, after 72 hours of transfection (Fig. 3.9A). For MDA-MB-231 cells, 
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Figure 3.9 
Intracellular ATP content of (A) MCF-7 cells, (B) MDA-MB-231 cells after AS 
treatment with I C 5 0 concentration for 72 hours. The procedure was described in 




3.1.5 Effect of Antisense Oligonucleotides against Glut 5 on Glut 5 
RNA Expression of MCF-7 Cells and MDA-MB-231 Cells by 
RT-PCR and Real-Time PCR 
3.1.5.1 RT-PCR 
Theoretically, AS can suppress the target gene expression in both 
transcriptional and translational levels. To investigate whether AS against Glut 5 can 
suppress the Glut 5 RNA level, RT-PCR was performed. After AS 1-4 treatments, 
the total RNA from the cells were extracted and reverse transcribed to cDNA. Two 
pairs of primers were used, namely p-actin and Glut 5. They gave the product of 
approximately 600bp and 700bp respectively. The mRNA levels after AS treatments 
of both cell lines were shown in Fig. 3.10 and Tables 3.2 and 3.3 showed the ratio of 
the band intensity of Glut 5 of the treated sample compared to that of the negative 
control. The band intensity was measured by a densitometer. 
From the result, it can be shown that in MCF-7 cells, there was a 
down-regulation of Glut 5 RNA expression after AS treatment with I C 5 0 
concentration, 72 hour post-transfection, when compared with that of negative 
) 
control. Similar results were obtained for MDA-MB-231 cells (Fig.3.10B). It 
suggested that Glut 5 can suppress the expression of Glut 5 mRNA in both cell lines. 
82 
Results 
CTL S AS1 AS2 ASS AS4 
G l u t s BSBB^^ B^B 5 8 i b . p . 
Mc. ^ B ^ s a a -.p. 
(A) 
帥 I I I I I I B -p . 
(B) 
Figure 3.10 
mRNA expression of Glut 5 in (A) MCF-7 cells, (B) MDA-MB-231 cells, after AS 
treatment with I C 5 0 concentration, 72-hour post-transfection. The procedure was 





Ratio of band intensity of Glut 5 mRNA of treated sample compared to that of the 
negative control of untreated MCF-7 cells (Fig. 3.10). The band intensity was 
measured by a densitometer. The experiment was repeated for three times and data 
shown were mean 士 S.D. 
Band Intensity Ratio 
yS-actin Glut 5 
Negative Control 29840 25580 -
S 27410 24160 1.03 ±0.02 
A S l 30450 15020 0.58 士 0.05 
AS 2 31060 10350 0.39 ±0.01 
AS 3 24970 12380 0.58 ±0.03 





Ratio of band intensity of Glut 5 mRNA of treated sample compared to that of the 
negative control of untreated MDA-MB-231 cells (Fig. 3.10). The band intensity 
was measured by a densitometer. The experiment was repeated for three times and 
data shown were mean ± S.D. 
Band Intensity Ratio 
/3-actin Glut 5 
Negative Control 33500 29230 -
S 31870 24160 0.87 士 0.05 
A S l 37350 14210 0.44 ±0.03 
AS 2 35320 10760 0.35 ±0.02 
AS 3 33290 10960 0.38 ±0.04 




3.1.5.2 Real-Time PCR 
The expression of Glut 5 RNA was investigated using real-time PCR. 
Real-time RT-PCR can be used for quantitation of the initial amount of template 
specifically. The real-time PCR system is based on the detection and quantitation of 
a fluorescent reporter. This signal increases in direct proportion to the amount of 
PCR product in a reaction. By recording the amount of fluorescence emission at 
each cycle, it is possible to monitor the PCR reaction during exponential phase 
where the first significant increase in the amount of PCR product correlates to the 
initial amount of target template. Threshold cycle (CT) is the cycle number at which 
the fluorescence emission exceeds the fixed threshold. The initial amount of target 
template is inversely proportional to the CT. The expression level of the target gene 
which is represented by "Mean fold change" can be calculated as follows: 
Mean fold change = 
Where AACj = ACj of target gene of sample -ACT of target gene control 
, ACT = CT of target gene - Cj of 18S rRNA 
I 
Mean fold change of target gene represents the amount of target gene. Mean 
fold change of negative control was set to be 1. For down-regulation of target gene, 
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the mean fold change is ranged from 0-1; for up-regulation of target gene, the mean 
fold change is greater than 1. 
To detect the initial amount of Glut 5 RNA after AS treatment, primers for 
Glut 5 conjugated with a fluorescence dye "FAM" and primers for 18S rRNA 
conjugated with "VIC" were used. 18S rRNA was used for normalization and 
calculation. 
The mean fold changes of Glut 5 RNA expression after AS 1-4 treatments in 
MCF-7 cells and MDA-MB-231 cells were tabulated in Table 3.4. In both cell lines, 
the mean fold changes of all AS treatments were less than 1. This showed that Glut 5 





Mean fold change of Glut 5 RNA after AS 1-4 treatments in MCF-7 cells and 
MDA-MB-231 cells, using real-time PGR. The procedure was described in section 
2.2.8. Data shown were mean 士 S.D., n = 3. 
Mean Fold Change 
Treatment MCF-7 Cells MDA-MB-231 Cells 
Negative Control 1 1 
S 0.86 土 0.05 1.074 土 0.08 
A S l 0.574 士 0.02 0.653 ± 0.05 
AS 2 0.523 ±0.03 0.624 ±0.05 
AS 3 0.553 士 0.06 0.533 士 0.04 




3.1.6 Effect of Antisense Oligonucleotides on Glut 5 Protein 
Expression of MCF-7 Cells and MDA-MB-231 Cells by 
Western Blot Analysis 
As mentioned before, AS can suppress the target gene expression in both 
transcriptional and translational levels. To investigate whether AS against Glut 5 can 
suppress the Glut 5 protein level, Western blot analysis was performed, according to 
the procedure described in section 2.2.9. The protein levels after AS 1-4 treatments 
of both cell lines were shown in Fig. 3.11 and Tables 3.5 and 3.6 showed the ratios 
of the band intensity of Glut 5 protein of treated sample to that of the negative 
control. The band intensity was measured by a densitometer. 
From the result, it can be shown that in MCF-7 cells, there was a 
suppression of Glut 5 protein level after AS 1-4 treatments with respective I C 5 0 
concentrations, 72 hour post-transfection, when compared with that of the negative 
control (Fig.3.11A). Similar results were obtained for MDA-MB-231 cells (Fig. 
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Figure 3.11 
Protein expression of Glut 5 in (A) MCF-7 cells, (B) MDA-MB-231 cells, after AS 
1-4 treatments with respective I C 5 0 concentrations, 72-hour post-transfection. The 





Ratio of band intensity of Glut 5 protein of treated sample to that of the negative 
control of untreated MCF-7 cells (Fig. 3.11). The band intensity was measured by a 
densitometer. The experiment was repeated for three times and data shown were 
mean 士 S.D. 
Band Intensity Ratio 
/3-actm G l u t s 
Negative Control 116800 78530 -
S 113600 76580 1.00 士 0.03 
AS 1 119400 51920 0.65 士 0.04 
AS 2 124000 44780 0.54 ±0.04 
AS 3 136300 45430 0.50 ±0.07 





Ratio of band intensity of Glut 5 protein of treated sample to that of the negative 
control of untreated MDA-MB-231 cells (Fig.3.11). The band intensity was 
measured by a densitometer. The experiment was repeated for three times and data 
shown were mean 士 S.D. 
Band Intensity Ratio 
/3-actin Glut 5 
Negative Control 135600 127200 -
S 130500 125900 1.03 ±0.02 
A S l 131800 87770 0.71 ±0.06 
AS 2 123310 72980 0.63 ± 0.03 
AS 3 121400 73460 0.65 士 0.4 




3.1.7 Effect of Antisense Oligonucleotides against Glut 5 on Change 
in Cell Cycle Pattern of MCF-7 Cells and MDA-MB-231 Cells 
by Flow Cytometry, Using PI Staining 
To investigate whether AS treatment alter the cell cycle pattern of MCF-7 
and MDA-MB-231 cells, flow cytometry using propidium iodide (PI) was used. PI 
is the most common dye to assess the DNA content quantitatively. PI binds to DNA 
and emits red fluorescence which can be detected by flow cytometer FL-2 channel. 
We can estimate the percentage of cells in sub Gi, Gl , S and G2/M phase using a 
computer program WinMDI. 
The cell cycle patterns of MCF-7 cells after AS 1-4 treatments, 72 hours 
post transfection, were shown in Fig. 3.12 and the percentage of each phase was 
tabulated in Table 3.7. From the result, it was found that there is no accumulation of 
cell population in Gl , S and G2/M phase, but in sub Gi phase (Fig. 3.12 and Table 
3.7). For MDA-MB-231, similar results were obtained (Fig. 3.13 and Table 3.8). For 
both cell lines, no cell cycle arrest was observed in all treatments, but there might be 





Negative Control Sense Control 
Si 
I ft I 
„ . 安. 
UJ I LU 
• J • ‘ � 
0 1023 0 1023 
FL-2A FL-2A 
A S 1 A S 2 
CN, CN 
CI CI 




W L M i w w w r f 
° 0 1023 0 1023 
FL-2A FL-2A 




> 1 > I 
LU UJ 
° 0 1023 0 1D23 
‘ FL-2A FL-2A 
) 
Figure 3.12 
Cell cycle pattern of MCF-7 cells after AS 1-4 treatments, with respective I C 5 0 





The percentage distribution of Gi, S，G2/M and Sub Gi phase of MCF-7 cells after 
AS 1-4 treatments, with respective I C 5 0 concentration, 72 hours post transfection. 
Phase Gi S G2/M Sub Gi 
Negative control 48.73 15.63 16.05 1.92 
Sense 50.28 14.56 16.67 4.28 
A S l 45.80 13.91 13.46 14.47 
AS 2 45.98 14.4 14.92 12.70 
AS 3 42.12 13.98 15.51 14.24 
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Figure 3.13 
Cell cycle pattern of MDA-MB-231 cells after AS 1-4 treatments, with respective 





The percentage distribution of Gi, S, G2/M and Sub Gi phase of MDA-MB-231 cells 
after AS 1 - 4 treatments, with respective I C 5 0 concentration, 72 hours post 
transfection. 
Phase Gi S G2/M Sub Gi 
Negative control 53.85 11.57 22.06 3.02 
Sense 54.63 11.22 20.93 3.72 
A S l 38.48 12.52 18.02 25.38 
AS 2 37.49 11.57 15.44 30.52 
AS 3 33.04 12.13 14.94 33.48 




3.1.8 Effect of Antisense Oligonucleotides against Glut 5 on 
Induction of Apoptosis of MCF-7 Cells and MDA-MB-231 
Cells by Flow Cytometry, Using Annexin V-FITC Staining 
To investigate whether AS treatment to MCF-7 cells and MDA-MB-231 
cells induce apoptosis, flow cytometry using Annexin V-FITC staining was 
performed. Annexin V is a specific phosphatidyl serine (PS) binding protein, in 
which PS are normally found in the inner membrane of the plasma membrane and is 
externalized to the outer surface of the membrane during apoptosis. Annexin V is 
conjugated to FITC which emits green fluorescence and can be detected by FL-1 
channel of the flow cytometer. At the same time, PI was used to identify the dead 
cells and detected by FL-3. Early apoptotic cells are annexin V positive but PI 
negative, while late apoptosis and necrosis cells are both annexin V and PI positive. 
The detection of apoptosis and necrosis after AS 1-4 treatments with 
respective I C 5 0 concentration, 72 hours post-transfection of M C F - 7 cells and 
MDA-MB-231 cells were shown in Fig.3.14 and Fig.3.15. From the results, it 
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Figure 3.14 
Assessment of apoptosis and necrosis in MCF-7 cells, after AS 1-4 treatments with 
respective IC50 concentration, 72 hours post-transfection using Annexin V-FITC/PI. 
The procedure was described in section 2.2.10.2. 
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Figure 3.15 
Assessment of apoptosis and necrosis in MDA-MB-231 cells, after AS 1-4 
treatments with respective IC50 concentration, 72 hours post-transfection using 
Annexin V-FITC/PI. The procedure was described in section 2.2.10.2. 
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3.2 In Vivo Study 
3.2.1 Animal Model: Nude Mice 
Tumor bearing female nude mice, aged 4-6 weeks, were used as animal model. 
As the MCF-7 cells are dependent on estrogen for growth, a 0.72mg, 60-day 
releasing 17|3-estradiol pellet (Innovative Research of America) was inoculated s.c. 
into the anterior part before inoculation of cancer cells. The establishment of 
tumor-bearing animal model and the treatment schedule in section 2.2.9 were 
followed. 
3.2.2 Effect of Antisense Oligonucleotides against Glut 5 on the 
MCF-7 Cells-Bearing Nude Mice 
3.2.2.1 Change of Body Weight of the Tumor-Bearing Nude Mice 
The weight of the tumor-bearing mice in all groups were recorded before 
each time of injection (Fig. 3.16, 3.17 & 3.18). First injection day was noted as Day 
0. Data shown were mean土 S.D., n=10. From the results, the body weights of the 
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Figure 3.16 
Effect of S against Glut 5 on the body weights of the MCF-7 cells-bearing nude mice. 
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Figure 3.17 
Effect of AS against Glut 5 on the body weights of the MCF-7 cells-bearing nude 
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Figure 3.18 
Comparison of effect of S with AS on body weights of the MCF-7 cells-bearing 




3.2.2.2 Tumor Growth Rate 
The tumor volume of the MCF-7 cells-bearing nude mice in all groups were 
recorded before each time of injection (Fig. 3.19 & 3.20). First injection day was 
noted as Day 0. Data shown were mean土 S.D.，n=10. The growth rate of the tumor 
and percentage of inhibition of tumor growth was shown in Table 3.9. 
After 8 doses, on day 16，the tumor-bearing mice were sacrificed and the 
tumor was excised. The tumor volume of each mouse in each group was recorded 
(Fig. 3.19 & 3.20). 
From the results, it showed that after AS treatment, the tumor volume still 
increased progressively, but with less growth rate when compared with the sense 
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Effect of AS against Glut 5 on the tumor growth in the MCF-7 cells-bearing nude 
mice. The procedure was described in section 2.2.11. First injection day was noted 
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Figure 3.20 
Comparison of the tumor volume of AS treatment with S treatment in MCF-7 
cells-bearing nude mice. First injection day was noted as Day 0. Data shown were 





The growth rate of tumor in each group and percentage of inhibition on the growth 
of tumor in MCF-7 cells-bearing nude mice (with respect to PBS control). 
Growth rate % of inhibition 
(mm^/day) (Respect to PBS CTL) 
PBS control 7.4912 -
Sense 7.2187 -0.8% 




3.2.2.3 Glut 5 RNA Expression by Real-Time PGR 
The expression of Glut 5 RNA in the tumor was investigated using real-time 
PGR. Total RNA was extracted from the tumor homogenate obtained on day 16 and 
reverse transcribed to cDNA which is the template for the PCR. The C j values of 
each group of mice with different treatments were tabulated in table 3.10. From the 
results, it showed that Ct values increased after AS treatment, when compared with 





Mean fold change of Glut 5 RNA expression from each group of MCF-7 
cells-bearing mice with different treatments, by real time PCR. Data shown were 
mean 士 S.D., n = 3. 
Treatment Mean Fold Change 
PBS CTL 1 
Sense 1.131 士 0.12 




3.2.2.4 Glut 5 Protein Expression by Western Blotting 
The Glut 5 protein expression level after AS treatment to the MCF-7 
cells-bearing nude mice was investigated by Western blotting. Total protein was 
extracted from the tumor homogenate obtained on day 16, using the procedure in 
section 2.2.9. The Glut 5 protein expression level was shown in Fig. 3.21. As 
expected, the protein level was decreased with AS treatment, when compared with 
that of the PBS and sense control. 
I l l 
Results 
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Figure 3.21 





3.2.3 Assessment of Side Effects of Antisense Oligonucleotides 
against Glut 5，by Measuring the Plasma Enzymes Level 
To assess the side effects of AS on the internal organs of MCF-7 
cells-bearing nude mice, measurement of plasma enzymes activities can be used as 
the diagnostic tool. To detect heart damage, creatine kinase (CK) and lactate 
dehydrogenase (LD) can be used. To detect liver damage, aspartate transaminase 
(AST) and alanine transaminase (ALT) can be used. The tissue distribution of these 
enzymes is shown in table 3.11. These enzymes are normally absent or only small 
amount are present in the plasma. The increase in the plasma enzyme activities 




Tissue distribution in plasma of the AST, ALT, CK and LD. 
Enzyme Tissue Distribution 
AST Liver cells, cardiac cells, skeletal muscle and erythrocytes. 
ALT Large amount in liver, lesser extent in skeletal muscle, kidney 
and heart 
CK High concentration in cardiac cells, low concentration in 
skeletal muscle and in brain 
LD High concentration in cardiac cells, low concentration in 
skeletal muscle, liver, kidney, brain and erythrocytes 
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After AS treatment for 15 days, there was no significant change of AST & 
ALT activities in the plasma (Fig.3.22), when compared with that of the PBS control 
and sense control. This means that no liver damage was detected in the MCF-7 
cells-bearing nude mice after AS treatment. 
Similarly, there is no significant change of CK & LD activities in the plasma 
(Fig.3.23), when compared with that of the PBS control and sense control. This 
means that no heart damage was detected in these mice after AS treatment. 
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Figure 3.22 
Effect of AS on (A) AST, (B) ALT activities in the plasma of MCF-7 cells-bearing 
nude mice. 1x10^ MCF-7 cells in 0.1ml PBS was inoculated into the nude mice s.c. 
and allowed to grow until the tumor size reached about 50mm^ Treatment was 
started by injecting 20mg/kg/day of oligonucleotides adjacent to the tumor in each 
nude mice for 8 doses, every other day. For PBS-control group, 0.1ml of PBS was 
injected. The drugs were administrated into the tumor-bearing mice s.c., with 
constant volume of 0.1 ml/mouse/injection. After 8 doses, the mice were sacrificed 
and the plasma was collected to perform enzyme assays. Data shown were mean土 
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Effect of AS on (A) CK (B) LD activities in the plasma of MCF-7 cells-bearing nude 
mice, bearing nude mice. 1x10^ MCF-7 cells in 0.1ml PBS was inoculated into the 
nude mice s.c. and allowed to grow until the tumor size reached about 50mm^ 
‘ T r e a t m e n t was started by injecting 20mg/kg/day of oligonucleotides adjacent to the 
tumor in each nude mice for 8 doses, every other day. For PBS-control group, 0.1ml 
of PBS was injected. The drugs were administrated into the tumor-bearing mice s.c., 
with constant volume of 0.Iml/mouse/injection. After 8 doses, the mice were 
sacrificed and the plasma was collected to perform enzyme assays. Data shown were 








4,1 Antisense Oligonucleotides against Glut 5 on Human 
Breast Cancer 
4.1.1 Antisense Oligonucleotides Strategy 
Antisense oligonucleotides provide a simple and efficient approach for 
developing highly specific drugs, as they can alter the gene expression sequence 
specifically. It is very useful to treat any diseases in which the disease causing genes 
have been identified. Once the disease causing genes, or genes related to growth of 
the disease have been defined, antisense oligonucleotides can be designed against 
the genes and alter the gene expression specifically. 
There are many genes related to the development and growth of the cancer. 
For example, insulin-like-growth factors (IGFs) (Muti et aL, 2002) and glucose 
transporters (Gluts) (Chen et al” 2002) are found to contribute to breast cancer 
development. If we use AS to alter the expression of these genes, it will lead to a 
change in a cascade of events, and finally causing anti-proliferative or cytotoxic 
effect on the cancer. Some findings suggested that AS against Glut 1 was effective in 
, c a u s i n g cytotoxic effect on MCF-7 and HepG-2 cells (Chen et a/.,2002). 
t 
The sequence selection is a critical factor in designing antisense 
oligonucleotides. Some studies suggested that phosphorothioated oligonucleotides 
(PS-Oligo) containing CpG motifs have immunostimulatory activity (Vollmer et al., 
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2004). Also, the presence of secondary structures can interfere with antisense 
activity by allowing the AS to bind to unintended protein targets. AS is not easy to 
be designed and not as simple as designing primers for other assays, e.g. PCR 
reactions. Target site selection, choice of oligonucleotide sequences, chemical 
modification, minimization of protein binding and other competing factors should be 
addressed when designing the AS (Agrawal and Kandimalla, 2000). There are 
several limitations of using AS. The stability in vivo is the major problem. Ideally, it 
should be resistant to enzymes degradation, should induce RNase H activity, without 
altering the affinity for target gene and the specificity. To enhance the stability of the 
AS, modifications can be made (Section 1.3.4, Fig. 1.7). At the moment, there is no 
such modification that can fit the above criteria. The cost of using AS for therapeutic 
use is high. Although the AS with phosphorothioation at each base to enhance the 
stability, is commercially available, it is expensive. 
The cellular uptake is another problem of AS strategy. Using cationic lipid 
as carrier system can improve the cellular uptake. Also, cationic, cell-penetrating 
peptide conjugated to the AS can enhance the membrane permeability and the 
resistance to nucleases. The peptide is 6-30 amino acids in length and linked to a 
24-mer AS. The naked oligonucleotides are extensively taken up across the 
mammalian plasma membranes in a non-endocytic manner. It does not induce the 
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immune response in vivo (Oehlke et al., 2002). 
Although there are many limitations of AS strategy, AS is still an effective 
approach in down regulating the target gene expression in a sequence specific 
manner. 
Antisense technology composed of different kinds, e.g. antisense DNA, 
siRNA and PNA, etc. Antisense DNA is single-stranded, negatively charged and 
complementary to the target gene. It triggers RNase H or steric blocking of 
ribosomes at some selected sequence of the mRNA. siRNA composed of small 
double-stranded RNA oligonucleotides with overhanging extremities and a length of 
21/22 bases. It is the substrate of a natural intracellular protein complex called RNAi 
induced silencing complex (RISC), and can performing post-transcriptional gene 
silencing in mammalian cells (Hammond et al” 2000). The gene silencing 
mechanism is totally different from that of antisense DNA. PNA is a nucleic acid 
mimic in which the deoxyribose phosphate backbone has been replaced by a peptide 
polymer to which the bases are linked (Larsen et al., 1999). It is chemically related 
to DNA. The gene silencing mechanism is similar to that of antisense DNA. 
) 
In this project, antisense DNA was used. Antisense DNA is easily 
synthesized. A large variety of modifications can improve the stability, membrane 
permeability and the mode of action. It provides transient antisense effect to the cells. 
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Therefore, antisense DNA is suitable for inhibition of gene expression. 15 base pairs 
oligonucleotide was chosen. From previous study by our colleague Mr. Chan KK, it 
showed that 15 mer oligonucleotide was more efficient when compared with 21 mer, 
because of its shorter length. The uptake was increased from at least 2 folds in 
MCF-7 cells to 53 folds in MDA-MB-231 cells (The thesis of Chan KK, 2000). If 
shorter oligonucleotide was used, e.g. 6-12 mer, the specificity was decreased. The 
short oligonucleotide can bind to many important genes and this may affect the 
functions of our body. Since, statistically, the minimum number of nucleotides that 
occurs just once in the human genome is, on average, 13 (Alama et al., 1997). Thus, 
15 mer oligonucleotide is the best choice and should be able to bind selectively to a 




4.1.2 Role of Glut 5 in Breast Cancer 
Glut 5 is expressed in the intestine and sperm, etc. Glut 5 helps in the entry of 
fructose into the cells and provide energy to support their high metabolic rate in 
addition to glucose. Fructose is phosphorylated on C-1 by fructokinase yielding 
fructose-1-phosphate (FIP). FIP is then converted to dihydroxyacetone phosphate 
(DHPA) and glyceraldehyde. The DHAP is converted, by triose phosphate isomerase, 
to glyceraldehyde-3 phosphate (G3P) and enters glycolysis. The glyceraldehyde can 
be phosphorylated to G3P by glyceraldehyde kinase. DHAP and G3P can then enter 
glycolysis (Elliott et al., 2002). 
Cancer cells exhibit enhanced rates of glycolysis when compared with 
normal cells (Warberg, 1956). The enhanced metabolic rate is supported by 
increased uptake of glucose or other hexoses. The hexoses enter cells via Gluts. It 
was found that Glut 1，2, 4 and 5 were expressed in the breast cancer cells 
(Zamora-Leon et al., 1996). The role of Glut 1 in human breast cancer has been 
studied extensively (Grover-McKay et al.’ 1998, Laudanski et al., 2003), but the role 
of Glut 5 in breast cancer has not been well studied. The only paper concerning Glut 
t 
5 in breast cancer was by Zamora-Leon et al (1996). Therefore, it is a challenging 
task to study Glut 5 in breast cancer. 
As mentioned in previous part, only Glut 5, also called fructose transporter, 
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was highly expressed in breast cancer cells, but absent in normal breast cells 
(Zamora-Leon et al., 1996). Glut 5 exhibits selectively for fructose transport, with a 
Km of 6mM. In addition, fructose transport was not inhibited by cytochalasin B, a , 
competitive inhibitor of glucose transporters (Tatibouet et aL, 2000). The result 
suggested that Glut 5 did not possess specificity toward glucose. 
The expression of Glut 5 mRNA and protein are regulated by the fructose 
uptake by the cells. As mentioned before, the energy requirement of breast cancer 
cells is high because of their high metabolic rate. They do not fiilly utilize the 
glucose entered. The catabolism of glucose stops after glycolysis. Thus, small -
amount of energy is released by each glucose molecule. The presence of Glut 5 is 
important because this enables breast cancer cells to have a specialized ability to 
transport fructose, in which fructose is a metabolic substrate used by only a few 
human tissues. So, breast cancer cells can get more metabolic substrate, in addition 
to glucose, in meeting their energy requirements. Although the physiological 
concentration of fructose is low (50-200|amol/L) (Shiota et al., 2002), fructose still 
, h a s important physiological role for providing energy to the breast cancer cells. 
I 
From my previous study, in the supply of different concentration of fructose, both 
cell lines grew in a dose dependent manner (Data not shown in the thesis). This can 
show that the growth of both MCF-7 cells and MDA-MB-231 cells depend on the 
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supply of fructose. During breast cancer development, the expression level of Glut 5 
increased in breast cancer cells. It was observed from the cell lines MCF-7 cells and 
MDA-MD-231 cells (Fig. 1.10). MCF-7 cells mimic the early stage of breast cancer, 




4.1.3 Effects of Tamoxifen on MCF-7 cells and MDA-MB-231 cells 
Tamoxifen is the most common anti-cancer drug for treating breast cancer. It 
has been used for more than 20 years. The cytotoxic effects of tamoxifen on MCF-7 
cell line and MDA-MB-231 cell line were investigated using MTT assay (Fig. 3.1). 
After 48 or 72 hour incubation, the I C 5 0 of tamoxifen on MCF-7 cells were \5\iM 
and 12.5)iM respectively. For MDA-MB-231 cells, the I C 5 0 of tamoxifen were 40|iM 
and 35|xM respectively. 
From the results, it showed that tamoxifen is more effective in treating MCF-7 
cell line, which is an ER-positive cell line and mimics the early stage of breast 
cancer, than MDA-MB-231 cell line, which is an ER-negative cell line and mimics 
the late stage of breast cancer. The results are not surprising as tamoxifen exerts its 
action through the estrogen receptor (ER). It acts as a competitive inhibitor of the 
estrogen. If the dosage is too high, it may cause many side effects e.g. occurrence of 
hot flashes, increase risk of endometrial cancer and thromboembolic disease, etc. 
Also, many tumors eventually become resistant to treatment with tamoxifen 
(Sainsbury, 2004). The possible causes of tamoxifen resistance are absence or loss of 
) 
ER, mutant ER, tamoxifen-stimulated growth of tumor and cross-talk among growth 
factor signaling pathways (Osborne, 1998). 
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4.2 In Vitro Study of Antisense Oligonucleotides against 
Glut 5 on Breast Cancer Cells 
The cytotoxic effects of AS 1 to AS 4, flanking different regions of the Glut 5 
mRNA, were investigated by MTT assay. Sense sequence was complementary to AS 
1，which flanking around the start codon. It was used to illustrate the non-specific 
effect. The non-specific effect was mainly due to the binding of sense sequence to 
some intracellular proteins in a sequence-independent manner. This would be toxic 
to the cells (Wagner, 1994). The cytotoxicity to MCF-7 cells and MDA-MB-231 
cells of sense oligonucleotides increased when high concentrations were used. From 
the results, it showed that AS 1-4 against Glut 5 caused cytotoxic effect to MCF-7 
cells and MDA-MB-231 cells in dose dependent manner, 72-hour post transfection. 
On MCF-7 cells, the I C 5 0 of AS 1，AS 2, AS 3 and AS 4 were 220nM, 190nM， 
300nM and 220nM, respectively. AS 2 is the most effective one in killing MCF-7 
cells. On MDA-MB-231 cells, the I C 5 0 of AS 1, AS 2，AS 3 and AS 4 were 410nM， 
400nM, 400nM and 470nM，respectively. Both AS 2 and AS 3 are effective in killing 
MDA-MB-231 cells. In conclusion, AS 2 is the most effective antisense 
» 
oligonucleotide. AS 2 is complemenary to the coding region near 5’ end. AS 2 was 
chosen to be used in in vivo study. The difference of I C 5 0 in treating different cell 
lines was due to the fact that the expression level of Glut 5 is different in these two 
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cell lines (Fig. 1.10). It is now known that MDA-MB-231 cells have more Glut 5 
than that of MCF-7 cells (Zamora-Leon et al,, 1996). This means targeting Glut 5 by 
antisense oligonucleotide can be used for treating all stages of breast cancer. 
The incubation time after transfection was chosen to be 72 hours (3 days). 
The oligonucleotides started to degrade after 72 hours in vitro (Crooke et al., 1995). 
Therefore, the antisense effects should be detected before 72 hours. 
MDA-MB-231 cells expresses more Glut 5 when compared with MCF-7 
cells. Thus, it is reasonable to use a higher concentration of AS to cause 50% 
cytotoxicity. Although the concentration of AS used to cause 50% cytotoxicity was 
high in MDA-MB-231 cells, the concentration was still low when compared with 
using tamoxifen by 100 folds. As mentioned in previous part, the IC50 of tamoxifen 
in treating MCF-7 cells and MDA-MB-231 cells were 12.5|iM and 35|iM, 
respectively. Also, tamoxifen causes a lot of side effects. Therefore, AS is more 
effective in treating both early stage (estrogen responsive) and late stage (estrogen 
irresponsive) breast cancer. The probable side effects of AS were investigated in vivo 
, and will be discussed in latter part of this thesis. 
Glut 5 is responsible for transporting fructose. We hypothesized that AS 
against Glut 5 can down-regulate the gene expression of Glut 5 and affect the 
fructose uptake. Therefore, the effect of AS against Glut 5 on fructose uptake was 
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investigated. Also, glucose uptake was tested to see whether the glucose uptake is 
affected, using the 2-deoxy-D-[l-^H] glucose uptake assay. This can test the 
specificity of AS. If the AS is only specific for Glut 5, the glucose uptake should not 
be affected. 
From the result, after AS 1-4 treatments with respective I C 5 0 concentration, 
the -fructose uptake in MCF-7 cells were decreased when compared with 
the negative control and the sense control, after 72 hours of transfection (Fig. 3.7A). 
For MDA-MB-231 cells, a similar result was obtained (Fig. 3.7B). This suggested 
that the Glut 5 expression may be reduced and contributed to the decrease of 
D-[Ui4c]-fmctose uptake. 
For 2-deoxy-D-[l-^H] glucose uptake, after AS 1-4 treatments with 
respective I C 5 0 concentration, the 2-deoxy-D-[l-^H] glucose was not changed in 
both cell lines after 72 hours post transfection (Fig. 3.8). This implied that AS 
against Glut 5 was only specific to Glut 5, but not the other isoforms. Also, the 
decrease in fructose uptake did not cause an increase in glucose transport for 
compensation. 
i 
Glut 5 is highly expressed in breast cancer cells, but absent in normal breast 
cells. This finding indicated that breast cancer cells may have a specialized capacity 
to transport fructose which is a rare metabolic substrate to be used by only a few 
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human tissues. If fructose is the metabolic substrate for the breast cancer cells, after 
the inhibition of fructose uptake, the ATP content in the cells should be changed. 
Therefore, intracellular ATP assay was done to investigate the effect of AS on the 
breast cancer cells. 
From the result, it showed that the intracellular ATP content decreased after 
AS 1-4 treatments with respective I C 5 0 concentration, 72 hours post-transfection, in 
both cell lines. The percentage of reduction was about 30-40%. This suggested that 
AS against Glut 5 can inhibit the fructose uptake and reduce the catabolism of 
fructose to release ATP. Fructose may be the major metabolic substrate of breast 
cancer cells. 
As mentioned before, the percentage of reduction of ATP content was about 
30-40%, but it contributed to about 50% of cytotoxicity, as I C 5 0 concentration were 
used. So, we speculated that Glut 5 may have functions other than transporting 
fructose, just like Glut 1 and Glut 3 can transport glucose and the metabolite of 
ascorbic acids (Rumsey et al, 1997). Glut 1 can also transport D-mannose, water 
, ( F i s c h b a r g et al, 1990，Gould et al, 1991)，galactose (Takakura et al, 1991) and 
) 
glucosamine (Uldry et al., 2002). Further investigation is needed to confirm this 
hypothesis. 
Theoretically, AS can suppress the target gene expression in both 
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transcriptional and translational levels. To investigate whether AS against Glut 5 can 
suppress the Glut 5 mRNA level, traditional RT-PCR was performed to find out the 
amount of Glut 5 mRNA expression at the end-point. This can only provide the 
preliminary result. It would be further confirmed by real-time PCR. Real time PCR 
collects data in the exponential growth phase. The increase in reporter fluorescent 
signals is directly proportional to the number of amplicons generated. This is a more 
effective and accurate approach to detect the RNA expression. 
We hypothesized that the reduction of fructose uptake and intracellular ATP 
content were accompanied by the reduction of Glut 5 mRNA and protein expression. 
Therefore, RT-PCR and Western blot analysis were done to test this hypothesis. 
The results of traditional and real-time PCR showed that in both cell lines, 
there was down-regulation (-40-50%) of Glut 5 RNA after AS treatment with I C 5 0 
concentration, 72 hour post-transfection, when compared with the negative control. 
From the result of Western blot analysis, the Glut 5 protein level was decreased after 
AS treatment. These results suggested that the AS against Glut 5 can cause gene 
silencing by either inhibition of the transcription of target gene by DNA triplex 
t 
formation, degradation of Glut 5 mRNA by RNase H or inhibition of translation by 
steric blocking which prevents ribosome from approaching the mRNA. 
In the previous part, it can be shown that AS against Glut 5 possessed an 
131 
Discussion 
anti-tumor effect on breast cancer cell lines. The mechanism of the anti-tumor effect 
was investigated by flow cytometry. Propidium iodide (PI) was used to detect the 
change in cell cycle pattern. PI is the most common dye to assess the DNA content 
quantitatively. PI binds to DNA and emits red fluorescence and detected by flow 
cytometer FL-2 channel. We can estimate the percentage of cells in sub Gi, Gi, S 
and G2/M phases using a computer program WinMDI. Many anti-tumor drugs 
inhibit the growth of cancer cells by disturbing the cell cycle, causing cell cycle 
arrest in Gi phase, e.g. tamoxifen blocks the transition from Gi to S phase 
(Lykkesfeldt et al., 1984). 
From the results, it was found that there was no accumulation of cell 
population in Gi, S and G2/M phase, but in sub Gi phase (Fig. 3.12 and table 3.7). 
For MDA-MB-231 cells, similar results were obtained (Fig. 3.13 and table 3.8). For 
both cell lines, no cell cycle arrest was observed in all treatments, but there might be 
occurance of apoptosis, as there was an accumulation of cells in sub G! phase. 
Apoptosis is programmed cell death which involved a cascade of events and signal 
transduction. Therefore, annexin V-FITC dye was used to find out whether apoptosis 
has occurred after AS treatment. Annexin V is a specific phosphatidylserine (PS) 
binding protein, in which PS are normally found in the inner membrane of the 
plasma membrane and is externalized to the outer surface of the membrane during 
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apoptosis. Annexin V is conjugated to FITC which emits green fluorescence and is 
detected by FL-1 channel of the flow cytometer. At the same time, PI was used to 
identify the dead cells and detected by FL-3. Early apoptotic cells are annexin V 
positive but PI negative, while late apoptosis and necrosis cells are both annexin V 
and PI positive. From the result, it suggested that all AS induced apoptosis after 72 
hour recovery in both cell lines. Apoptosis resulted from nutrient deprivation, which 
may then induce activation of signal transduction, e.g. kinases like mitogen 
activation protein kinase (MAPK), c-Jun, etc., change in the redox state of the cell, 
or generation of free radicals (Aft et al； 2002). 
When compare the results of PI staining with annexin V-FITC staining, it 
was found that the percentage of cells present in sub Gi phase in all AS treated cell 
lines was lower than that of early apoptotic phase in annexin V-FITC staining. As 
mentioned in previous part, PI stains DNA and sub Gi phase represents cells present 
in late apoptotic in which the DNA was fragmented by the action of caspase 3. 
Caspase 3 is a key factor for initiation of DNA fragmentation. MCF-7 cells do not 
express caspase 3 gene (Kurokawa et al” 1999). Therefore, DNA fragmentation was 
) 
not detected during apoptosis, but still have PS extemalization. Thus, it gave a little 
signal in sub Gi phase ( � 1 0 % ) in PI staining, and high cell population in annexin 
V-FITC staining (-45%). MDA-MB-231 cells express caspase 3 (Yang et al., 2003) 
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and DNA fragmentation occurs during apoptosis. Thus the percentages of cells 
present in sub Gi phase in PI staining after AS treatment were similar in the early 




4.3 In Vivo Study of Antisense Oligonucleotides against 
Glut 5 on Breast Cancer 
The effects of antisense oligonucleotides (AS) against Glut 5 have been 
tested in vitro and the result was encouraging. The probable side effects of AS 
should be investigated before clinical trial. Therefore, in vivo study was conducted to 
assess the effect of AS and the probable side effects to the internal organs of the 
MCF-7 cells-bearing nude mice. 
Breast cancer is a solid tumor formed under the skin in breast. Drug can be 
directly injected adjacent to the tumor. This is more effective than intravenous (i.v.) 
injection as the AS would degrade rapidly in the bloodstream. Direct transmission of 
DNA into the tumor has proved to be feasible and safe at reducing tumor growth in 
experimental procedure in mice (Nable et al, 1993). 
Previous studies of the effect of tamoxifen on MCF-7 cells-bearing nude 
mice showed that it caused transient stimulation of tumor growth, followed by a 
prolonged stationary phase. The growth of tumor resumed. Growth inhibition was 
also observed with anti-estrogens and was dose dependent. The 
I 
hormone-independent MDA-MB-231 cells were not influenced by anti-estrogen 
treatment. Endocrine therapy by anti-estrogen treatment inhibits tumor cell 
proliferation in nude mice, but does not cause tumor regression or loss of cell 
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4.3 In Vivo Study of Antisense Oligonucleotides against 
Glut 5 on Breast Cancer 
The effects of antisense oligonucleotides (AS) against Glut 5 have been 
tested in vitro and the result was encouraging. The probable side effects of AS 
should be investigated before clinical trial. Therefore, in vivo study was conducted to 
assess the effect of AS and the probable side effects to the internal organs of the 
MCF-7 cells-bearing nude mice. 
Breast cancer is a solid tumor formed under the skin in breast. Drug can be 
directly injected adjacent to the tumor. This is more effective than intravenous (i.v.) 
injection as the AS would degrade rapidly in the bloodstream. Direct transmission of 
DNA into the tumor has proved to be feasible and safe at reducing tumor growth in 
experimental procedure in mice (Nable et al., 1993). 
Previous studies of the effect of tamoxifen on MCF-7 cells-bearing nude 
mice showed that it caused transient stimulation of tumor growth, followed by a 
prolonged stationary phase. The growth of tumor resumed. Growth inhibition was 
also observed with anti-estrogens and was dose dependent. The 
hormone-independent MDA-MB-231 cells were not influenced by anti-estrogen 
treatment. Endocrine therapy by anti-estrogen treatment inhibits tumor cell 




viability (Osborne et al., 1985). 
In the experiment, female nude mice were used, because their immune 
system is defective. The inoculation of human tumor cells will not cause any 
immune response to reject the xenograft. MCF-7 cells were inoculated into their 
back with a 60-day releasing 17/3-estradiol pellet to support its growth. The tumor 
cells were allowed to grow until a solid tumor was formed. The initial size of tumor 




4.3.1 Effects of Antisense Oligonucleotides against Glut 5 on Body 
Weight and Tumor Size 
The effects of AS against Glut 5 on the body weight and tumor size of 
MCF-7 cells-bearing nude mice were investigated. We have demonstrated that the 
anti-tumor effect of AS against Glut 5 on tumor growth was due to specific antisense 
effect. Because there was no abrogation of tumor proliferation in any of the control 
groups. 
After the injection of AS, it was absorbed and circulated in the bloodstream. 
The half-life is about 40-60 hours (Crooke et al., 1994). This is the reason why the 
AS was injected in alternative days, but not in consecutive days. Plasma clearance of 
AS is rapid, broad tissue distribution occurs, and elimination is by nuclease 
metabolism. Metabolism is mediated by exo- and endonucleases that result in shorter 
oligonucleotides and nucleosides that are degraded by normal metabolic pathways 
(Crooke, 2004). A literature review suggested that in monkeys, rodents, and dogs, 
there was accumulation of AS and metabolites occurs in the form of basophilic 
granules in various tissues, including the kidney, lymph nodes and liver (Farman and 
Kombrust, 2003), with the liver accumulating most rapidly. 
The body weights of the mice were measured before each dose and it 
remained quite constant throughout the experiment. There was no significant change 
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of body weight with AS treatment when compared with the PBS and sense control. 
For the tumor size, it was measured before each injection. The tumor in all 
group of mice grew progressively, but with less growth rate in AS treated group. The 
growth rate of PBS, sense control and AS treated groups were 7.4912, 7.2187 and 
3.845 mmVday respectively. The result showed that AS against Glut 5 is effective in 
treating breast cancer in vivo. Further investigation should be done on the 
mechanism, clearance of AS in vivo. Also, higher doses should be used to test 
whether AS is effective in a dose-dependent manner. 
4.3.2 Expression Level of Glut 5 of the Tumor 
The Glut 5 expression level was investigated using real-time PCR and 
Western blot analysis. From the result, it showed that after the injection of AS, the 
Glut 5 RNA and protein level decreased. This suggested that AS against Glut 5 can 
block the transcription and translation of Glut 5. The reduction of Glut 5 expression 
leads to decrease of fructose uptake or probably other important essential substrates 




AS against Glut 5 injection adjacent to tumor 
1 r 
Inhibit Glut 5 mRNA and protein expression 
y 
Decrease nutrient (Fructose or probably others) supply, cannot 
generate enough ATP for growth 
，r 
Slow down cell proliferation or cell death occur 
Figure 4.1 
Flow chart of consequences of antisense oligonucleotides against Glut 5 treatment to 




4.3.3 Assessment of Side Effects of Antisense Oligonucleotides 
against Glut 5，by Measuring the Plasma Enzymes Level 
To assess the probable side effects of AS on the internal organs of MCF-7 
cells-bearing nude mice, measurement of plasma enzymes activities can be used as 
diagnostic tool. To detect heart damage, creatine kinase (CK) and lactate 
dehydrogenase (LD) can be used. To detect liver damage, aspartate transaminase 
(AST) and alanine transaminase (ALT) can be used. 
After AS treatment, there is no significant change of AST and ALT activities 
in the plasma, when compared with PBS control and sense control. This meant AS 
did not cause liver damage with this dosage. Similarly, there is no significant change 
of CK and LD activities in the plasma, when compared with PBS control and sense 
control. This meant AS treatment did not cause heart damage. In addition, no death 
and hemolysis occurred in all groups. 
Note that only one dosage, 20mg/kg/day was used. The probable side 
effects of higher dosages e.g. 40mg/kg/day, should be assessed. High dosage of AS 
may cause splenomegaly, thrombocytopenia and severe elevation of AST and ALT 
I 
(Sarmiento et aL, 1994). Actually the side effects of AS depends on the dosage and 
the duration of administration. Further studies should be done on higher dosage and 
longer treatment schedule. 
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4.4 Possible Mechanisms of Antisense Oligonucleotides 
against Glut 5 on Breast Cancer 
The antisense oligonucleotides against Glut 5, AS 1-4, exert their effects on 
binding to the target nucleotide sequence directly through Waston and Cricks 
hybridization. The entry of AS was mediated by cationic liposomes. After the entry 
of an AS into the breast cancer cells, it binds to the target sequence and results in 
gene silencing, by inducing RNase H to degrade the DNA-RNA hybrid, forming 
DNA triplex or steric blocking of ribosome from binding to the mRNA. Thus, less 
amount of Glut 5 can be expressed and therefore, less fructose can be taken up by 
the breast cancer cells. From our study, fructose is an important metabolic substrate 
for breast cancer cells, this may induce energy deprivation and oxidative stress. 
Although the physiological concentration of fructose is low (50-200|imol/L) (Shiota 
et al., 2002), fructose still has an important physiological role for providing energy 
to the breast cancer cells. In a colon cancer cell line Caco-2, fructose can serve as a 
carbon and energy source and common dietary monosaccharides affect the efficiency 
of fructose metabolism (Ellwood et al., 1993). 
During breast cancer development, the expression level of Glut 5 increased. 
For glucose deprivation-induced oxidative stress, these cause cytotoxic effect to the 
breast cancer cells by activating signal transduction and increased expression of 
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genes associated with malignancy (Spitz et aL, 2000). Glucose deprivation-induced 
energy depletion stimulated mitochondrial death pathway cascade (Moley and 
Mueckler, 2000). We hypothesized that the situation is similar in fructose-induced 
deprivation. Further investigations should be done to confirm the hypothesis. 
AS against Glut 5 induced energy depletion. The reduction of intracellular 
ATP concentration may inhibit the action of P-glycoprotein, which is powered by 
ATP and pump drug out of the cells, results in drug resistance, e.g. usage of 
tamoxifen on late stage, hormone irresponsive breast cancer. The inhibition of 
p-glycoprotein pumping action can reduce multi-drug resistance in the cells. Ideally, 
combined treatment of antisense oligonucleotides against Glut 5 and the anti-cancer 
drug may have a synergistic effect. Glut 5 AS can reduce the gene expression of Glut 
5 and then decrease the fructose uptake. Thus, energy deprivation results and the 
pumping action of p-glycoprotein were inhibited. Then the anti-cancer drug can 










Future Prospectus and Conclusions 
5.1 Future Prospectus of Antisense Oligonucleotides 
5.1.1 Antisense Oligonucleotides and Treatment of Breast Cancer 
The antisense technology has been investigated extensively both in vitro 
and in vivo. It is a potential therapeutic agent in cancer, viral infections and genetic 
disorders, as well as a tool for studying the regulatory mechanisms in biological 
processes. But there are still many limitations for using antisense oligonucleotides, 
e.g. stability and delivery means, especially in vivo. These are the major hurdles to 
be overcome. It is necessary to create stronger and more selective affinity for RNA 
or duplex structures. Also, further investigation on antisense oligonucleotides should 
be done to provide the ability to cleave the target, and to enhance nuclease stability, 
cellular uptake and distribution, and in vivo tissue distribution, metabolism and 
clearance. The base, sugar and phosphate moieties of oligonucleotides can be 
modified. For clinical trial, the safety is the most important issue. 
In the present study, the effects of antisense oligonucleotides against Glut 5 
have been investigated. Further studies include usage of other forms of chemical 
modification, like conjugation to a short peptide to improve stability and membrane 
I 
permeability, study of the inter-relationship between other glucose transporter 
isoforms and the usage of Glut 5 AS, microarray study to detect the gene expression 
profile after Glut 5 AS treatment and to see whether the mechanism is similar to that 
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of glucose-induced energy deprivation. For in vivo study, sufficient 
pharmacokinetics should be done to define rational dosing schedules. Also, it is 
important to try the inoculation of MDA-MB-231 cells into the mice to test the 
effect of AS. This can provide a significant clinical influence on the treatment of 
breast cancer. As mentioned before, MDA-MB-231 cells mimic the late stage, 
hormone irresponsive breast cancer and tamoxifen is unable to treat this kind of 
cancer (Osborne et aL, 1985). Therefore, the effect of AS on MDA-MB-231 cells 
should be done. 
After evaluation of the antisense oligonucleotides against Glut 5’ it can be 
hopefully used for treatment of breast cancer. Combined treatment with anti-cancer 
drugs, e.g. doxorubicin, tamoxifen may further improve the efficiency in treating 
breast cancer. As antisense oligonucleotides (AS) against Glut 5 can reduce 
intracellular ATP content and thus inhibit the pumping action of p-glycoprotein. As a 
result, the anti-cancer drug can enter the cells without any barrier and exerts their 
effects, even in multi-drug resistant tumor cells. At the same time, 
nutrient-deprivation induced energy depletion induces cascade of events and finally 
I 
leads to apoptosis of cancer cells. Another approach is to combine antisense 
oligonucleotides against Glut 5 and Glut 1. AS against Glut 1 was studied 
extensively. The anti-tumor effects of Glut 1 AS on MCF-7 cells and HepG-2 cells 
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were investigated and it caused cytotoxic effect to both cell lines successfully (Chan 
et al., 1999，Chen et al, 2002). The combined treatment of AS against Glut 5 and 
Glut 1 may cause profound anti-tumor effects. But the toxicity and side effects on 
normal cells should be carefully addressed, as Glut 1 are present in almost all cells. 
AS against Glut 1 may affect the glucose uptake in the normal cells. If AS against 
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5.1.2 Role of Glut 5 in Breast Cancer 
Glut 5 is a fructose transporter. Glut 5 exhibits selectively for fructose 
transport, with a Km of 6mM. In addition, fructose transport was not inhibited by 
cytochalasin B, a competitive inhibitor of glucose transporters (Tatibouet et al., 
2000). The result suggested that Glut 5 did not possess specificity toward glucose. 
The presence of Glut 5 is important because this enables breast cancer cells to have a 
specialized ability to transport fructose, in which fructose is a metabolic substrate 
used by only a few human tissues. This is a survival advantage for the breast cancer 
cells. So, breast cancer cells can get more metabolic substrate, instead of glucose, in 
meeting the great energy requirements of breast cancer cells. 
Antisense oligonucleotides against Glut 5 can bring about effective 
cytotoxicity to the cells because of nutrient deprivation. It is speculated that Glut 5 
may possess another functions instead of transporting fructose. It may transport 
some nutrients which are important for growth e.g. essential amino acids, fatty acids 
or vitamin, etc, just like Glut 1 and Glut 3 can transport glucose and the metabolite 
of ascorbic acids (Rumsey et al, 1997). Up till now, there is no published paper 
» 
about the substrate specificity of Glut 5. Further investigation should be done on 
Glut 5 kinetics study, to find out the Km toward different important nutrients. This 
can help us understand the role of Glut 5 in breast cancer development. 
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5.2 Conclusions and Remarks 
Antisense represents the regulation of gene expression by short 
oligonucleotides or oligonucleotide mimics, which relies on the formation of Waston 
and Crick hydrogen bonds between the antisense oligomer and the complementary 
mRNA strand, thereby providing target specificity of the agent. In the present study, 
antisense oligonucleotides against Glut 5 are effective to treat human breast cancer 
undoubtedly. Glut 5 AS binds to the target nucleotide sequence and results in gene 
silencing by either inducing RNase H to degrade the DNA-RNA hybrid, DNA 
triplex formation to block transcription, or steric blocking of ribosome to contact 
with mRNA. In in vitro study, Glut 5 AS caused cytotoxicity on MCF-7 cells and 
MDA-MB-231 cells by lowering the capacity to transport nutrients into the cells, 
and induced energy deprivation. The AS silencing mechanism was confirmed by the 
reduction of mRNA and protein expression. Apoptosis was the final step of energy 
deprivation. The flow of Glut 5 AS treatment was summarized in Fig. 5.1. In in vivo 
study, administration of Glut 5 AS reduced the tumor growth rate and it did not 
cause any side effect in mice, e.g. damage to internal organs, hemolysis and death. 
> 
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AS against Glut 5 
+ 
Inhibit Glut 5 mRNA and protein expression 
，r 
Decrease nutrient (fructose) supply, cannot generate enough ATP for growth 
1 r 
Energy deprivation and trigger cascade of signal transduction 
y 
Slow down cell proliferation or cell death occur 
Figure 5.1 
Flow chart of consequences of antisense oligonucleotides against Glut 5 treatments 
in MCF-7 cells and MDA-MB-231 cells. 
I 
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The ultimate goal of our future works is to develop an effective approach to 
human breast cancer treatment by using novel chemically modified antisense 
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